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Gene therapy is widely considered to have great therapeutic potential for a wide 
variety of diseases that occur due to malfunctioning genes. To achieve therapeu-
tic effects, genetic material needs to reach target organelles within cells, and 
thus must overcome complex intra and extracellular barriers. Because the 
physicochemical properties of nucleic acids, such as their high molecular 
weight and negative net charge, prohibit translocation over cell membranes, the 
successful application of gene therapy relies on the development of gene deliv-
ery vehicles.  
Cell-penetrating peptides (CPPs) are one class of non-viral transport vectors 
that have been widely exploited to deliver nucleic acids into cells. CPPs can be 
up to 30 amino acids long, are typically cationic and/or amphipathic, and can 
facilitate both the condensation of large nucleic acid molecules such as plasmid 
DNA (pDNA) and their intracellular delivery.  
The main purpose of the research presented in this dissertation was to 
develop an efficient CPP in cell culture that is applicable for systemic gene 
delivery in vivo, and has potential to treat diseases caused by aberrant gene 
expression, such as cancer. First, we characterized various aspects of peptide 
based gene delivery, such as potential gene induction efficacy and the uptake 
mechanisms in cell culture. Next we evaluated the potential for CPP-mediated 
pDNA delivery after systemic administration in mice and found that improve-
ments were required, including the need to achieve tumor specific gene 
delivery. For that, we evaluated various strategies such as the conjugation of 
either targeting peptides or polyethyleneglycol (PEG) molecules to the CPPs. 
The latter strategy improved the biocompatibility of CPP/pDNA complexes and 
permitted us to shield the universal transfection property of CPPs, which could 
be further activated specifically in specific tumor tissues and induce gene 
expression. We also optimized the complex formulation to improve their gene 
delivery properties without PEGylation and characterized other CPP properties 
such as cationic charge density and fatty acid modification. We found both to be 
important aspects that govern CPP-mediated gene delivery not only in cell cul-
ture, but also in vivo. In conclusion, the potential of CPP-based gene delivery 
system could be further extended for gene therapy applications in relevant dis-
ease models.  
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Advances and improvements in genetics and biotechnology have provided a 
completely new understanding about how the human genome functions. An 
ever-expanding amount of data is becoming available to identify the causes 
underlying disorders caused by aberrant gene expression. In light of this pro-
gress, gene therapy has received renewed consideration as a potential treatment 
strategy for a very wide variety of diseases that occur due to malfunctioning 
genes, including cancer. Gene therapy applies strategies that modify the expres-
sion of an individual’s genes or correct the expression of abnormal genes. To 
achieve these objectives, therapeutic nucleic acids must reach their targets 
within cells, and thus must overcome complex intra and extracellular barriers. 
Because the physicochemical properties of nucleic acids preclude their spon-
taneous translocation into cells, successfully applying gene therapy relies on the 
development of gene delivery vectors, the most challenging part of developing 
gene therapy-based applications.  
After initial failures, the development of viral vectors proved to effectively 
deliver their cargo, however, their utilization is still associated with drawbacks, 
which creates potential for the use of non-viral gene delivery vectors. Numerous 
studies have demonstrated their efficacy to deliver genetic material into cells, 
however, the effectiveness of non-viral gene delivery vectors is often reduced 
when applied for in vivo gene delivery. While significant advances have been 
made in this field, and several cationic polymers and lipid-based materials have 
reached preclinical and clinical studies, not one single non-viral vector has been 
granted a marketing license after decades of studies.  
Cell-penetrating peptides (CPPs) are a relatively new class of non-viral 
transport vector that has considerable potential for both drug delivery and the 
delivery of genetic material. They can both condense nucleic acids into nano-
sized complexes and initiate their uptake into cells. CPPs share common traits 
with other non-viral vectors, including their property of universal transfection in 
cell cultures and difficulties using them in vivo. First, the work presented in this 
dissertation demonstrates the potential of CPPs to deliver genes in cell culture. 
Next, we present efforts to translate the potential of this non-viral gene delivery 
platform for the optimized gene delivery in vivo. The approaches presented 
herein could provide a new means to deliver therapeutic nucleic acids into rele-
vant disease models. 
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1. LITERATURE OVERVIEW 
1.1 Gene therapy 
Advances and technological improvements have made it both possible and fea-
sible to sequence human genome [1], [2]. These advances have also signifi-
cantly deepened our understanding of the mechanisms that cause many genetic 
disorders. Taken together, recent developments have greatly expanded the 
potential use of gene therapy as a therapeutic intervention. Although therapeutic 
applications are now reaching clinical trials [3], gene therapy has not yet real-
ized its potential, which may require a major breakthrough to achieve. Yet, in 
light of recent technological advances, gene therapy is considered to be in the 
midst of a renaissance [3], [4]. In recent years several gene therapy products 
have been authorized for marketing in different countries (Table 1) and expand-
ing rate of clinical trials have emerged [5].  
Gene therapy could be defined as a set of strategies that either modify the 
expression of an individual’s genes or correct abnormal genes. Each of these 
strategies involve the administration of a specific DNA (or RNA) molecule [6]. 
In EU regulation, gene therapy has been placed under the guidelines for 
advanced therapy medicinal products (ATMPs), which refers to medicinal prod-
ucts for human use. Besides gene therapy products, this class of treatment also 
includes somatic cell therapy and tissue engineering products [7]. This clearly 
demonstrates that gene therapy is now considered to be a more realistic 
approach than it was twenty years ago, when the first clinical trials were con-
ducted [8], [9]. Applications are not restricted to the delivery of genes into cells 
because the definition now includes constructing or manipulating cells or tissues 
whose genome has already been modified. This simultaneously opens up a new 
venue for applications, and a number of issues that have yet to be addressed.  
 
 
Table 1. Gene therapy products approved for marketing 
Gene therapy 
product 







Head and neck 
squamous cell 
carcinoma 
Viral TP53 [10] 
Rexin-G 2007 
Philippines 
















Viral LPL  [15], [16] 
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One of the most important milestones for the development of gene therapy 
could be considered the approval to market Glybera® in Europe [15], [16]. This 
is a gene therapy product for the treatment of a metabolic disease, lipoprotein 
lipase deficiency (LPLD, incidence of ~1/500 000), where the gene that encodes 
lipoprotein lipase is administered via a viral vector after intramuscular (i.m.) 
injection. Its efficacy has been evaluated in three clinical trials where the long 
term expression of this protein has been achieved, together with therapeutic 
effects [17]. 
Cystic fibrosis (CF) is another disease which treatment has been often 
associated with gene therapy. It is a monogenic autosomal recessive disorder 
that affects about 70000 people worldwide and is caused by a mutated gene that 
encodes the cystic fibrosis transmembrane conductance regulator (CFTR) pro-
tein, which is a cAMP regulated anion channel expressed on the apical surface 
of epithelial cells that lining airways, pancreatic ducts, and other tissues [18]. 
The affected cells are located in an environment filled with mucous, which 
makes gene delivery extremely difficult and necessitates the need for repeated 
administration. Cationic lipid nanoparticles, which are a non-viral gene delivery 
vehicles, have been harnessed for CF gene therapy [19].  
There are also several trials where genetic material has been delivered ex 
vivo by viral vectors into hematopoietic stem cells for the treatment of β-thalas-
semia [20], Wiskott-Aldrich syndrome [21] and X-linked severe combined 
immunodeficiency [22]. These examples rely on an improved viral gene deliv-
ery method, and highlight the importance of validating and studying other rele-
vant targets to address the needs of emerging and advanced gene modulation 
technologies. Furthermore, it is important to investigate alternative delivery 
vectors that have the potential to lead gene therapy into completely new level.  
 
 
1.1.1 Practical aspects about the  
design of gene expression vectors 
To deliver therapeutic genes into cells it is common that the gene of interest is 
inserted into a plasmid expression vector (pDNA) of prokaryotic origin. These 
expression vectors contain the elements required to initiate gene expression, 
such as promoters and their enhancer sequences and an antibiotic resistance 
gene is commonly available for the production of expression molecules. Being 
of bacterial origin, pDNA contains unmethylated CpG sequences, which are 
recognized by the host's immune system, and more specifically, by Toll-like 
receptors, which, in turn, could lead to the development of an immune reaction 
[23], [24]. Although it is highly probable that these sequences are initially 
shielded by the gene delivery vector, once they have dissociated from the deliv-
ery vector, unmethylated CpG sequences will be silenced and eventually dis-
carded [25]. To avoid this, gene expression vectors used for gene therapy 
should be designed carefully with reduced CpG content to avoid an immune 
response and enable sustained gene expression [26], [27], [28]. Furthermore, it 
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is possible to remove all of the bacterial sequences that are unnecessary to 
express the required genes via the minicircle DNA strategy. Advantages to this 
approach have been reported both in vitro and in vivo [29], [30], and although 
constructing these such expression vectors was initially considered to be labori-
ous, technical improvements have made it possible to produce them in higher 
quantities [31]. 
Another aspect to consider is the choice of promoters. The most commonly 
used viral SV40 or CMV driven expression cassettes provide rapid gene expres-
sion [32], which can be beneficial to study the effect of the gene delivery rea-
gent, however, for therapeutic applications, prolonged gene expression is more 
desirable to avoid repeated administrations. For that, the human elongation 
factor 1 (EF1) promoter alone or in combined with CMV-derived enhancer 
elements can be beneficial [27] .  
 
 
1.1.2 Regulation of gene expression with  
nucleic acid-based technologies 
Originally, gene therapy research targeted monogenic disorders but recent 
advances in biotechnology have opened very intriguing and potent possibilities 
to carry out gene therapy via short synthetic nucleic acids. RNA interference 
(RNAi) is a naturally occurring process that silences the expression of specific 
genes at the post-transcriptional level. The ability to silence genes using double 
stranded RNA (dsRNA), was first characterized in 1998 [33], followed by the 
delivery of a synthetic dsRNA molecule into mammalian cells that silenced a 
gene via RNAi using synthetic short interfering RNAs (siRNAs) [34]. This 
technology has since been widely used in a variety of applications and has even 
reached into clinical trials [35], [36].  
RNAi technology relays on the delivery of siRNA molecules into the cell 
cytosol where the RNA-induced silencing complex (RISC) is available to medi-
ate gene knockdown. siRNAs, the effector molecules of RISC, are 21–23 
nucleotides long and commonly possess modifications [37], [38] to make them 
more stable against extra- and intracellular enzymatic influences and to some 
extent these modifications limit off-target effects [39]. Once siRNA is taken up 
by the RISC complex, passenger strand is excluded and the guide strand then 
binds to the target mRNA. Thereafter, the RNase of RISC cleaves the mRNA, 
which leads to rapid degradation of target RNA, followed by reduced gene 
expression.  
Another approach to silence genes via RNAi is to express short hairpin RNA 
(shRNA) molecules inside cells [40], [41] using pDNA expression vectors. The 
silencing mechanism also relies on the RISC complex, however, the shRNA, 
expressed by the pDNA vector, must first be processed to 21–22 nucleotide 
long siRNAs by the Dicer molecule [42]. This technique uses the endogenous 
processing machinery to produce siRNA from shRNA encoding pDNA, and 
potentially allows for persistent gene silencing using lower copy numbers of 
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effector molecules thereby resulting in less off-target effects and greater safety 
[43]. 
RNAi is a very appealing technology for cancer treatment due to its ability to 
simultaneously silence several targets, however, the size of siRNAs limits their 
translocation over cellular membranes yet are small enough to be excreted by 
the kidneys if administered as a single agent. For RNAi to become an effective 
therapeutic intervention, these limitations must be met and a number of other 
issues addressed: (i) effective delivery, (ii) possible off-target effects, and (iii) 
pharmacokinetics and pharmacodynamics [43]. Non-targeted delivery of siRNA 
molecules leads to their accumulation in liver and possible uptake by hepato-
cytes. Because of this, several RNAi gene therapy applications have targeted the 
liver. To achieve selective delivery, incorporating siRNA into nanoparticles 
[44] or direct conjugation with targeting moieties can be beneficial. One exam-
ple of binding a targeting moiety to siRNA is conjugating N-acetylgalactosa-
mine (GalNAc) to siRNA, which mediates hepatocyte uptake via an 
asialoglycoprotein receptor. This approach leads to efficient and durable gene 
silencing at low and well tolerated doses [45], [46]. The siRNA-conjugates that 
have reached the clinical trials have been reviewed by Wittrup and Lieberman 
[47]. 
Another very potent approach for advanced gene therapy, or more specifi-
cally genome editing, is a technology termed the CRISPR/Cas9 (clustered regu-
larly interspaced short palindromic repeats/CRISPR-associated nuclease 9) 
system. First described and derived from the adaptive immune system of the 
bacterium Streptococcus pyogenes [48], its first application in mammalian cells 
was reported in 2013 [49] and is now very broadly used for genome editing in 
various organisms, including humans and other mammals [50]. It is based on 
the cut-and-paste approach that removes aberrant genetic information and 
replaces it with functional sequences. CRISPR/Cas ribonucleoprotein complex 
is composed of endonuclease Cas9, needed to bind and cleave target DNA, and 
two single-stranded RNA molecules – CRISPR RNA (crRNA), which binds to 
a complementary DNA sequence and trans-activating RNA (tracrRNA). Cas9 
Induced breaks are repaired via two mechanisms. The most common is non 
homologous end-joining (NHEJ), which leads to the introduction of insertions 
and deletions at the break site. Although, due to its simplicity it is most com-
monly used but NHEJ is very error prone and alternative mechanisms are being 
developed. The more precise homology-directed repair (HDR) requires the 
delivery of an exogenous DNA repair template, together with components. This 
extra delivery step makes the HDR method much more difficult to apply, how-
ever, the benefits are very desirable and significant effort has been made to 
utilize HDR in practice [51],[52].  
As mentioned above, to apply genome editing in practice, all of the required 
components must be delivered into the target cells, because the ribonucleo-
protein complex involved is only natively expressed in bacteria. Mainly viral 
vectors are employed to deliver and express these components, however, the 
stable expression of Cas9 endonuclease has been shown to increase side-effects 
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[53] and because of that, non-viral and transient delivery systems may be more 
beneficial [52]. It has been reported that CRISPR/Cas enables the correction of 
genes such as CFTR that underlies CF [54] and a potential therapeutic treatment 
for Duchenne muscular dystrophy has been demonstrated [55]. The major 
advantage of the CRISPR/Cas system over RNAi is that once the genetic defect 
is repaired, the result is inheritable and, CRISPR/Cas can also be used to correct 
gene expression, while RNAi can only be used to mediate temporal gene 
silencing [56]. Due to its prokaryotic origin it is likely that the CRISPR/Cas 
approach will have less cross-reactions in eukaryotic cells and lead to a reduc-
tion in off-target effects. It is important to note that advances in the field of 
RNAi and the delivery of its components into cells has made a significant 
impact on applying CRISPR/Cas in practice and in the delivery and/or expres-
sion of its effector molecules. The lessons learned on how to increase the intra-
cellular stability of short synthetic RNA molecules and reduce their side-effects 
have made it both easier and faster to apply advanced nucleic acid-based thera-
pies [57]. So far, the major drawback for all gene therapy applications is still the 
method of delivery and advances in this field could lead to the blossoming of 
gene therapy into routine clinical practice.  
 
 
1.2 Non-viral gene delivery platforms  
As discussed above, several gene therapy strategies are available in the market 
or are under investigation in clinical trials. Viral vectors and advances made in 
this field have contributed significantly to the development of gene therapy, yet, 
these have not avoided the need for extensive optimization (particle modifica-
tion, loading capacity). This, together with persistent safety concerns such as 
immunogenicity and insertional mutagenesis [58], have driven research towards 
efficient and safe non-viral delivery platforms. These platforms typically use 
cationic polymers or lipids that complex genetic material into particles via 
electrostatic and/or hydrophobic interactions. Many of these have already 
reached preclinical evaluation and several have reached into clinical trials. 
However, not one single non-viral gene therapy product has been granted a 
market license.  
 
 
1.2.1 Barriers for non-viral gene delivery 
The biggest challenge for non-viral gene therapy lies in in vivo gene delivery. 
The common limitations for most of these systems are [59] : 
(i) relatively low efficacy of gene transfection into the target cells, 
(ii) physicochemical instability of the vector/DNA complexes, 
(iii) induced cytotoxicity.  
 
To achieve a bioeffect, the therapeutic material must be sufficiently stable in the 
hostile environments within the organism and overcome various extracellular 
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and intracellular barriers before reaching its intracellular target in a functional 
state. To some extent, delivery vectors can protect the therapeutic genetic mate-
rial with their ability to pack or condense nucleic acids. Administration of the 
therapeutic material is conventionally carried out using either oral or local 
administration, or intravenous injection (i.v.) [60]. Although local administra-
tion enables to avoid most of the the extracellular barriers, this method is not 
applicable for most genetic diseases, and thus systemic administration is pre-
ferred. Upon entering the blood stream, the therapeutic material is immediately 
affected by blood cells, degradative proteins, complement proteins, and retic-
ulo-endothelial system (RES) recognition, all of which lead to rapid inactivation 
or even aggregation. This typically results in decreased gene delivery efficien-
cies, and, in the case of large aggregates, may trigger toxic reactions due to lung 
embolization.  
Physicochemical parameters such as surface charge and size are important 
factors that determine the fate of delivery complexes. A net positive charge 
reduces the aggregation between particles in formulation solution through 
electrostatic repulsion, however, once in the bloodstream they rapidly associate 
with negatively charged serum albumins and red blood cells (RBCs), which 
possess a negative surface charge [61]. In addition, the particles can interact 
with vascular endothelial cells and engulfed via phagocytosis. Another aspect is 
the size of preformed complexes and the size they obtain once they have 
reached into bloodstream. Although large aggregates may induce toxic effects, 
particles that are too small are rapidly excreted from the body through glomeruli 
in the kidney [60], so it is important to optimize the size they attain in the 
bloodstream.  
To reach targets in the brain, the therapeutic material must pass the blood-
brain barrier (BBB), which consists of brain capillary endothelial cells that do 
not have fenestrations, have extensive tight junctions (TJs), and very sparse 
pinocytotic vesicular transport [62]. This physical barrier actively regulates the 
transport and access of molecules to brain cells, and only very low molecular 
weight molecules are able to diffuse through the TJs; All other nutrients cross 
this barrier via transporters [63] [64]. The BBB is a selective barrier that pos-
sess a significant challenge for the delivery of therapeutic agents into the brain. 
However, with our increasing knowledge about neurodegenerative diseases and 
glioblastomas, the impetus to target these issues is also growing and gene ther-
apy could be a prospective treatment method. It has been observed that growing 
brain tumors induce TJs to open and provide a slight therapeutic window for the 
delivery of therapeutic molecules, however, no significant therapeutic effects 
have been accomplished by taking advantage of these open junctions and this 
delivery strategy allows molecules that can be toxic to neurons access to the 
brain, which may lead to permanent damage and severe effects [65]. In general, 
no delivery method should provoke permanent damage to either the BBB or the 
brain. 
Once gene delivery complexes traverse the barriers present after systemic 
administration and reach the vicinity of their target cells, they must translocate 
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over the cellular membrane and overcome many intracellular barriers. Several 
strategies are used to bind delivery complexes to specific receptors or fuse them 
with cellular membranes. Usually non-viral vectors are taken up by receptor-
dependent endocytosis and employing or initiating this inherent process enables 
the delivery of particles safely, and leaves cellular membranes intact. However, 
the benefits of endosomal uptake are negated by endosomal escape. Several 
strategies have been used to meet this limitation, including the proton sponge 
strategy [66]. This relies on the presence of secondary and tertiary amines that 
have pKa values in a similar range as the endosomal and lysosomal pH, 5.5 – 6. 
During the acidification of endosomes, amines become protonated and this 
alters the osmolarity of the vesicles by increasing the influx of protons and 
counter-ions into the vesicles. This, in turn, leads to the uptake of additional 
water molecules, increasing osmotic pressure, swelling, and finally rupture of 
the vesicle. However, this classical proton sponge hypothesis has been recently 
challenged [67]. These authors did not observe the rupture of endosomes nor the 
release of intact vectors and nucleic acid complexes into the cytosol. Instead, 
these two components were released separately into the cytoplasm via local 
pores within the endosomal membrane. These intriguing results require further 
confirmation and could potentially offer a new means of designing efficient 
endosomal escapers.  
In many cases, once the therapeutic genetic materials have gained access to 
the cytosol, whether associated with the delivery vehicle or not, their journey is 
almost complete. However, some nucleic acids, including pDNA molecules, 
must traverse the passage across the nuclear membranes, which is another criti-
cal intracellular barrier. It is commonly accepted that pDNA gains access to the 
nucleus during cell division, at which time the nuclear membrane breaks down. 
This is mainly supported by the fact that only molecules smaller than 9 nm and 
up to 40kDa are able to diffuse through the nuclear pore complex [68]. Nucleic 
acids have a much higher molecular weight and size and thus are not able to 
diffuse through the nuclear membrane. Although there are some strategies avail-
able to target the nuclear pore complex, nuclear uptake mechanisms in general 
have been poorly studied and no excellent methods currently exist to induce the 
uptake of genetic material. Improving this situation will require further insight.  
 
 
1.2.2 Common cationic gene delivery  
reagents for in vivo administration 
Cationic polymers offer a means to condense nucleic acids into a nanoparticle 
core. The most commonly used polymers are polyethyleneimine (PEI) [69], 
[70], poly L-lysine (PLL) [69], chitosan [71], [72], poly(2-N-(dimethyl-
aminoethyl) methacrylate) (pDMAEMA) [73] and poly(amidoamine) 





Figure 1. The most common cationic polymers used in gene delivery  
 
 
Polyethyleneimine (Figure 1) is a polymer with high cationic charge-density 
potential, where every third atom is an amino nitrogen that can be protonated 
and it has been widely studied and used within gene delivery applications for 
two decades already [76]. PEI can be linear or branched with either a low or 
high molecular weight. The efficacy of gene delivery using low molecular 
weight PEI is moderate but is significantly less toxic than delivery using high 
molecular weight PEI. This polymer is able to condense and bind nucleic acids 
very efficiently and acts as a proton sponge within endosomes inside the cells, 
which is a useful property to induce endosomal escape when delivering nucleic 
acids into cells. PEI-mediated gene delivery has been reported in numerous 
applications, however, when utilizing it as a single delivery vector for systemic 
administration of pDNA, it induces significant gene expression in lungs [77]. 
These authors used a CMV-based luciferase encoding gene expression vector, 
L-PEI, that is able to induce gene expression starting from 103 (pDNA dose 20 
g) up to 107 (with pDNA dose 125 g) in relative light units per milligram of 
total protein content (RLU/mg). Naked pDNA administration in lungs induced 
gene expression levels up to only 103 RLU/mg. It was concluded that this gene 
expression was specifically induced in lung alveolar tissues, however, high gene 
expression was induced in other organs as well [77]. 
Besides its use as a single-component gene delivery vector, a receptor bind-
ing ligand transferrin (Tf) has been incorporated into PEI/pDNA complexes 
which leads to enhancement of transgene expression in a subcutanous mouse 
Neuro2a model after systemic administration, mainly by masking the high posi-
tive charge of PEI/pDNA complexes [78]. Another example is PEGylated PEI-
Tf/pDNA complexes, which, after systemic administration, enhanced gene 
induction in tumors. However, expression was also observed in different organs 
such as liver, lungs, and also near the injection site in tail [79]. Although 
PEGylation improved gene delivery in tumors and decreased it in lungs, it was 
obvious that complexes were still being taken up by non-tumor tissues – they 
could already transfect cells in tail and be taken up by lungs. This highlights the 
need to mask or shield the overall transfection potential of the cationic polymer 
so that it is indeed taken up or activated specifically in tumor tissues, thereby 
enabling efficient cancer gene therapy. Various ligand-targeting formulation 
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strategies for pDNA delivery have been compared, including the use of PEI and 
PEG [80]. The first approach involved covalent conjugation of a targeting-
ligand to PEI and this construct was used to complex pDNA and followed by 
attaching a PEG molecule. In the second approach, pDNA is condensed by PEI 
and these complexes are functionalized with PEG followed by attachment of a 
ligand to the distal end of the PEG. This resulted in particles that have both 
PEG and the targeting ligands on their surface. In the third approach, complexes 
were prepared in a single step by condensing the pDNA with a mixture of PEI, 
PEG-PEI, and ligand-PEG-PEI. The third strategy, although it used a different 
ligand, provided both the most efficient and significantly higher levels of gene 
induction in tumor tissues, while gene expression in other tissues, such as lung, 
remained modest [80], [81], [82]. This intriguing result suggests that the most 
efficient and optimal gene induction occurs using a formulation technique 
where all components are able to simultaneously complex pDNA, and also turns 
out to be the simplest method to functionalize pDNA/PEI complex with both 
PEG and a targeting ligand. 
Despite being very efficient in gene delivery, PEI-mediated systemic 
transfection has been associated with side-effects [83]. In this report [84], 
PEI/pDNA complexes were separated from excess free PEI and systemically 
delivered, thereby achieving reduced side-effects and reduced transfection effi-
cacy as well. They then used stepwise addition of free PEI to purified com-
plexes to optimize transfection efficiency while reducing side-effects. The 
authors of this study highlighted the importance of a free cationic fraction of the 
polymer. Nevertheless, PEI has successfully been used in several preclinical 
studies, and the formulations have been optimized and is now commercially 
available as an in-vivo gene delivery reagent [85]. 
Poly-L-Lysine or PLL has been extensively used for gene delivery. At 
physiological pH, the primaryamine group in lysine carries cationic charge 
and is the main source for nucleic acid complexation via electrostatic inter-
actions [86]. Higher molecular weight PLL is capable of complexing pDNA at a 
charge ratio (CR) of one (CR1), whereas lower molecular weight PLL is four 
times less efficient and requires higher concentrations to achieve similar effi-
cacy [87]. Although PLL/pDNA complexes form, they are considered to be 
toxic to cells, which significantly reduces their transfection potential. These 
limitations have been addressed to some degree using strategies such as 
PEGylation [88].  
One interesting application for PLL in gene delivery platforms is 
TerplexDNA, a DNA delivery vector that consists of three components: (i) 
balanced hydrophobicity and net surface charge between stearyl-poly(l-lysine), 
which is needed to condense negatively charged nucleic acids; (ii) low density 
lipoprotein (LDL) as a targeting moiety, and (iii) nucleic acid [89], [90]. Sys-
temic administration of Terplex DNA leads to significant enhancement of the 
half-life of pDNA compared with unformulated genetic material. Complexes 
distributed within several organs, mainly in lungs and kidneys, and gene expres-
sion was detected in liver, heart, and to a smaller extent in a lung [91]. The 
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authors also analyzed the potential of PLL alone and stearylated PLL to induce 
gene expression after systemic administration. Intriguingly, they did not detect 
any activity. It was also claimed, that Terplex DNA-induced gene expression is 
mediated via receptor-dependent endocytosis in hepatocytes, which express 
LDL receptors. These receptors are also expressed on the surface of both arte-
rial endothelial cells and myocytes and the availability of receptor-mediated 
gene delivery in heart opened up an opportunity to use gene therapy in heart 
diseases [92], [93].  
Poly(2-N(dimethylaminoethyl)methacrylate) or pDMAEMA (Figure 1) is 
considered to be a good alternative to PEI because of its reduced toxicity and 
significant buffering capacity. Its potential as a gene carrier vector was first 
studied in 1996 where it was compared with different cationic polymers. In this 
study it was found to have similar toxicity as the other polymers, however, it 
was reduced when bound with pDNA [94]. The reduced cytotoxicity, (IC50 ~ 
40 μg/ml, whereas for PEI it is ~ 30 μg/ml [95]), good buffering capacity, sim-
ple and more controlled synthesis method by using radical polymerization of the 
corresponding vinyl monomer, makes pDMAEMA a good candidate vector for 
gene delivery [96]. Indeed, one advanced example of pDMAEMA mediated 
gene delivery is to brain after adding a targeting ligand to PEGylated 
pDMAEMA and pDNA complexes. This formulation induced gene expression 
in several organs, including brain after systemic administration of 50g of com-
plexed pDNA [97]. Although undecorated complexes distributed more in liver 
and in kidneys, the possibility to target complexes in brain and achieve gene 
expression clearly demonstrates the feasibility of this system.  
Chitosan (Figure 1) is a biodegradable polysaccharide that is composed of  
d-glucosamine and N-acetyl-d-glucosamine linked by a (1→4) glycosidic 
linkage. Their cationic charge originates from primary amines and provides 
efficient DNA binding. The clear advantage that chitosan has over cationic 
polymers is its biodegradability, which leads to enhanced biocompatibility and 
reduced toxicity. Its molecular weight is very well correlated with the reduced 
size of their complexes with pDNA molecules – the smaller polymer molecular 
weight, the smaller complex size at the same CR [98]. Transfection efficacy 
depends not only on the size of the complexes, but also by their stability and 
pDNA release profile and together, these properties could contribute to 
transfection, thus, chitosan formulations with different molecular weights in an 
appropriate range should be considered [71].  
Cationic lipids were first studied for their ability to transfect pDNA already 
in 1987 [99] and are now the most commonly used non-viral gene delivery 
reagents. They are able to complex pDNA, and the resultant lipoplexes are 
considered non-immunogenic due to a lack of immunogenic proteins. Further-
more, they are easily modified to obtain desired properties, such as size, surface 
charge, or specific targeting moieties. Although hundreds of lipids have been 
developed for gene delivery purposes, they share similar features: They consist 
of three basic domains (i) a hydrophilic positively-charged headgroup (ii) a 
hydrophobic domain (aliphatic chains), and (iii) a spacer linking both parts [100]. 
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Usually, the hydrophilic headgroup is positively charged and interacts with and 
condenses nucleic acids electrostatically. Based on the structures of the hydro-
philic headgroups, they can be grouped into six categories [101]:  
1) quaternary ammonium headgroups, 
2) amines (primary, secondary, or tertiary amines), 
3) amino acids or peptides, 
4) guanidine headgroups (monoguanidinium or conjugates of guanidinium 
and other headgroups), 
5) heterocyclic headgroups,  
6) unusual headgroups. 
 
It is typical to first thoroughly study the structure-activity relationship of cati-
onic lipids to find favorable parameters for transfection. Cationic lipids are used 
in combination with neutral helper lipids to form liposomes and pack DNA, 
which together form a DNA delivery system that meets the stringent criteria 
presented for non-viral gene delivery platforms. Cationic lipid based transfec-
tion shares many similar properties with cationic polymer-based systems. 
Transfection is dependent on the chemical structure of the cationic lipid 
(charge, linker and hydrophobic moiety), the CR between the cationic lipid and 
the DNA, the structure and proportion of the helper lipid in the complexes, the 
size and structure of the liposomes, and the total number of lipoplexes added to 
the cells. These properties, together with the chemical structure of the cationic 
lipid, determines the nanocomplex properties with nucleic acid and its transfec-
tion potential [102]. For example, a significant lipid-mediated hepatic siRNA 
delivery in vivo into non-human primates was reported already a decade ago 
[44], but significant improvements where achieved with ionizable cationic 
lipids as a key lipid components of stable nucleic acid lipid particles, which 
resulted in very efficient endogenous gene-silencing (at siRNA dose of 0.1 
mg/kg) in hepatocytes of non-human primates [103]. 
 
 
1.2.3 Strategies for improvement for cancer gene delivery  
As mentioned above, gene therapy has been considered to be a very potent 
strategy for cancer therapy, due to the possibility of addressing several targets 
simultaneously. Furthermore, tumors possess several properties that enable 
improved gene delivery. 
In cancer gene therapy applications, genetic material is delivered to cells to 
[104]: 
 restore/correct mutations, 
 carry out gene expression modulation using RNAi, 
 produce cytotoxic or prodrug activating gene products, 
 reduce angiogenesis, 
 increase immune response against tumor-cells. 
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The universal requirements for gene delivery vectors also apply for cancer gene 
therapy, such as binding of genetic material and shielding this from degradative 
enzymes. In addition to these common traits, cancer gene therapy products must 
be exclusively associated with the tumor and its cells, which means that 
delivery vectors must target cancer cells or have a specific mechanism that 
affects only cell-types associated with the tumor to reduce side-effects which 
are typically present when utilizing conventional cancer therapeutics. For the 
vector to reach the cancer cells, extra- and intracellular obstacles must be over-
come. For that, a range of "smart" polymer based nanoparticles has been exten-
sively developed and studied in recent years [104]. They consist of different 
modules to achieve most optimal parameters to mediate efficient, yet safe 
genetic material delivery in cancer cells.  
Cationic gene delivery reagents have been improved using various modifica-
tions such as tuning the surface of the nanoparticles. One possibility to increase 
stability is the addition of a PEG molecule, which, as a hydrophilic polymer, 
increases the solubility of drugs. When incorporated into a nanocomplex sur-
face, it forms a hydrophilic exterior that sterically inhibits the binding of serum 
proteins, reduces opsonization and reduces clearance by RES [105]. The main 
disadvantage of PEGylation is reduced binding with target molecules, which 
has been called the PEG dilemma [106]. This dilemma can be avoided by 
incorporating PEG molecules on the surface of the particles via cleavable link-
ers. These linkers can be sensitive to specific stimulus such as certain enzymes, 
pH, temperature, ultrasound, or radiation [107], [108].  
Due to its intrinsic genetic variability and additional physiological barriers 
for drug delivery systems, the treatment of cancer is very challenging. Tumors 
have an altered microenvironment with a leaky vasculature, increased interstitial 
fluid pressure, a slightly acidic environment compared to other tissues, and poor 
lymphatic drainage. So far, the most successful strategy in preclinical studies 
has been a combined approach of chemotherapy with gene therapy approaches, 
provides a synergistic effect that may either increase drug efficacy and enhance 
gene therapy mediated bioeffect [104].  
Various approaches are used to deliver nanoparticles into tumor tissues. The 
first is passive targeting [109], [110], which is based on the accumulation of 
nanoparticles within tumors due to incomplete tumor vasculature through 
enhanced permeability and a retention effect [111]. Adding an active targeting 
moiety that increases the binding affinity further increases the availability of 
nanoparticles within tumor tissues. These moieties could be proteins, e.g. anti-
bodies and their fragments, peptides, small molecules, or carbohydrates [112]. 
One example is the targeted delivery of the P53 gene in tumors. TP53 is a tumor 
suppressor gene that encodes a protein critical for two of the pathways involved 
in regulating tumor cell growth – apoptosis and the regulation of angiogenesis. 
This gene becomes mutated in a wide variety of human tumors [113] and to 
correct this, a liposomal complex composed of pDNA that includes a correct 
version of TP53 is targeted to tumor cells by an anti-transferrin receptor single-
chain antibody. This complex sensitizes tumor cells to conventional cancer 
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therapy and has moved from preclinical studies to clinical trials [114]. Another 
recent example of the delivery of TP53 using pDNA relies on a more distinct 
targeting strategy, where branched PEI and tuned ratios of PEG, histidine, and 
glutamic acid form complexes with the pDNA. These are then targeted to the 
tumor via its acidic microenvironment, wherein charge reversal of the complex 
occurs and promotes cellular internalization, endosomal destabilization, and 
finally gene expression of TP53 pDNA [115]. Several similar strategies have 
potential to improve the delivery of nanocomplexes to tumors [112]. 
One strategy to target nanocomplexes to tumor cells is using single chain 
antibody fragments, which are derived from antibodies but their affinity and 
specificity have remained. In one report cationic liposomes have been decorated 
with antitransferrin receptor single-chain antibody fragment (TfRscFv) and used 
for tumor specific gene delivery [116]. These liposomes have been exploited for 
gene delivery to express truncated retinoblastoma protein (RB94), that exerts 
potent tumor cell growth suppression [117]. Systemic administration of these 
targeted liposomes to enabled to express RB94 and sensitized tumors to chemo-
therapy, leading to reduction in tumor growth [116]. This potent gene-delivery 
platform in combination with chemotherapy has now entered to phase I clinical 
study [118]. 
Tumors need very good nutrient and oxygen supply for development and 
growth, therefore the neovascularization occurs rapidly and several growth 
factors are overexpressed in almost majority of cancer types. One main regula-
tor of angiogenesis is vascular endothelial growth factor (VEGF), that is over-
expressed in most tumors and is closely associated with tumor growth and 
metastasis [119]. This makes the targeting of angiogenesis and VEGF-associ-
ated pathways highly desirable. In numerous reports the expression of VEGF is 
targeted with RNAi for cancer therapy. For example, PEGylated PEI has been 
targeted to tumors via targeting peptides such as Arg-Gly-Asp (RGD) peptide 
[120] or Ala-Pro-Arg-Pro-Gly (APRPG) peptide [121] to deliver siRNA against 
VEGF. In both these studies the reduction in tumor vessel density and the 
inhibition of tumor growth was observed. APRPG is peptide that has identified 
via phage display technology using mouse angiogenesis model, where it 
adhered to neovascular endothelial cells [122]. Authors also applied liposomes 
encapsulating drug against angiogenic endothelial cells and decorated with 





1.3 Cell-penetrating peptides 
Cell penetrating peptides (CPPs) are short, usually less than 30 amino acid-long 
cationic and/or amphipathic peptides that are able translocate cellular mem-
branes and deliver a wide variety of cargo into intracellular compartments 
[123]. A concise definition of what constitutes a CPP is relatively difficult to 
write, however, it is clear that all CPPs share several common properties: (1) 
they are peptides that consist of natural or non-natural amino acids that have 
possibly been modified with chemical entities that improve their delivery 
properties, (2) conventional CPPs carry a positive net charge, (3) they are able 
to translocate over cellular membranes, (4) and most importantly, they are able 
to deliver a wide variety of cargo. CPPs have been applied in numerous studies 
for drug delivery in vitro and in vivo, and function not only as a single-compo-
nent delivery vector, but also within comprehensive delivery platforms as a 
moiety to aid cellular translocation.  
 
 
1.3.1 Overview of history and classification 
The first evidence that proteins are taken up by cells was provided in 1988, 
when it was found that the trans-activator protein (TAT) from the human 
immunodeficiency virus type 1 (HIV-1) [124] is taken up by cells. It was found 
that only a portion of the 86 amino acid TAT protein was necessary for both 
cellular uptake and enzymatic activity. Further investigation of deletional 
mutants confirmed that TAT (37–57) entered cells [125]. This led to the discov-
ery of a penetratin CPP in 1994 [126] and the later Tat peptide [127].  
The development of a transportan peptide [128] and a study of its deletional 
analogs [129] underlies the beginning of second generation CPPs termed 
PepFects and NickFects. These have proven to be very efficient in the delivery 
of nucleic acids in a wide range of applications [130], [131], [132]. Another 
important milestone in the context of the work presented in this dissertation is 
the description of a non-covalent complex formation between CPPs and nucleic 
acids and their efficient internalization within cells. From a clinical point of 
view, one cannot overlook the development of the activatable CPP-based 
strategy (ACPP) by R. Tsien who used this approach in a preclinical study 
[133]. During the twenty years since CPPs were discovered, they have gained 
considerable attention by the scientific community, and, in a relatively short 
time, significant achievements have been made towards their clinical use, as 
evidenced by numerous studies of CPP-based applications in cell culture and 
also in preclinical disease models.  
There are several ways of classifying CPPs and one of them is based on their 
origin. Firstly, peptides derived from proteins such as Tat [127] and penetratin 
[126]. Secondly, chimeric CPPs, which have been combined from sequences 
obtained from different proteins. Such combination with NLS and with hydro-
phobic domain that associates with cell membranes is Pep1 [134]. Another 
example is MPG, where signal peptide, taken from HIV glycoprotein 41 is also 
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combined with NLS [135]. Another noteworthy chimeric peptide is transportan 
which has 27 amino acids of which the 12 aminoterminal amino acids originate 
from the neuropeptide galanin and 14 amino acids at the carboxyl terminus 
originate from mastoparan, connected via one single lysine [128]. Beyond this 
are purely synthetic peptides such as the polyarginine family [136], [137], MAP 
[138] and CADY [139]. 
 
A more useful method of classifying CPPs uses the peptide sequence and their 
interactions with lipid membranes, where the distribution of charged and hydro-
phobic amino acids are taken into account [140]. This classification system 
defines three classes of CPPs: 
(i) primary amphipathic, containing charged and hydrophobic regions in 
their primary sequence; 
(ii) secondary amphipathic, becoming amphipathic by obtaining secondary 
structures like -helix or -sheet; 
(iii) non-amphipathic, usually very cationic peptides.  
 
Characteristics such as amphipathicity and cationicity are one of the key factors 
that not only determine how CPPs associate with cell membrane components 
and translocate into cells, but in how they form CPP/cargo complexes.  
 
 
1.3.2 Uptake mechanism and endosomal release 
It is commonly accepted that CPPs gain intracellular access via two main 
mechanisms – by either the endocytotic pathway or via direct penetration 
(Figure 2). The mechanism for the cellular entry of CPPs is not universal, and 
depends on the CPP sequence, concentration, or other factors. The types of 
CPPs that interact with lipids and thus possess high membrane activity might 
occasionally cause transient membrane damage. Nonetheless a variety of 
mechanisms have been proposed to explain how they translocate through cellu-
lar membranes. These depend on the type of CPP, its concentration, and even 
the nature and properties of the cellular membrane, however, in all cases mecha-
nistic proof remains elusive.  
Despite this, it is commonly accepted that when linked with high-molecular 
weight cargo molecule such as nucleic acids, endosomal uptake is preferred. 
Endocytosis could be subdivided as phagocytosis, associated with macrophages, 
or pinocytosis, which is present in all types of cells. The latter can be further 
subdivided based on the proteins that are involved in vesicule formation, the 
size of the endosome that forms and its intracellular fate via different types of 
endocytosis such as clathrin- or caveolae-mediated endocytosis, macropino-
cytosis, and clathrin- and caveolae-independent endocytosis [141], [142], [143]. 
Although the above-mentioned mechanism is predominant, one cannot entirely 
exclude direct translocation of the CPP/cargo complexes. Receptor dependent 
endocytosis, for example, has been demonstrated for arginine rich peptides, 
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which are taken up by a chemokine receptor thereby stimulating macropin-
cytosis [144]. A chemokine receptor targeting ligand has been conjugated to the 
CPP Tat to make it more specific for cancer cells [145]. The involvement of 
receptor-mediated endocytosis has also been shown for CPP/oligonucleotide 
(ON) complexes, where participation of scavenger receptors mediate their 
uptake [146], [147]. 
Usually, CPP uptake mechanism studies are performed in cultured cells that 
are genetically highly identical and possess similar membrane components. 
Furthermore, the components present in the extracellular media are also well 
defined. A serious concern arises, when one would like to translate in vitro 
findings to in vivo conditions, where the uptake of CPPs could depend on the 
administration method (local or systemic). Hence, the properties of CPP and/or 
CPP-cargo complexes change due to the influence of unspecific interactions 
with extracellular components such as proteins and digestive enzymes. When 
administered systemically, interactions with the cells present in blood or that 
line blood vessels, could also have impact on CPP uptake in tissues. Taken 
together, the uptake mechanism by tissue cells could be different than the 
mechanisms described using cell culture models. Resolving this issue will 




Figure 2. Overview of CPP/nucleic acid complex formation strategies and their pos-
sible cellular uptake route 
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1.3.3 CPP mediated nucleic acid delivery 
Nucleic acid delivery is one of the most important applications of CPPs and 
many different peptide sequences used for this purpose appear in the literature. 
Various strategies are available to modify otherwise inefficient peptides to 
become more efficient in gene delivery, including the incorporation of CPPs 
into more comprehensive and efficient delivery systems [148].  
First and foremost, CPP-mediated gene delivery is based on the cationic 
nature of CPPs which are able to neutralize the negative charge of DNA. The 
most common complexation strategy for intracellular CPP-mediated nucleic 
acid delivery is non-covalent formulation (Figure 2). Several studies have 
shown that charge neutralization alone is insufficient to form active transfection 
complexes, but it is enhanced by certain modifications that can significantly 
improve the condensation of nucleic acids. The resultant nano-sized (~100–
300nm) particles are formed concurrently due to both electrostatic forces and 
hydrophobic interactions, thereby enabling efficient complex formation at lower 
peptide concentrations [149]. Less condensed complexes could be more sensi-
tive to enzymatic attack, which could contribute to a decrease in transfection 
efficacy in the presence of serum proteins, which has been challenging for some 
gene delivery platforms. Another method of forming complexes is to covalently 
attach the nucleic acid molecule to the CPPs with a linker. The main advantage 
of covalent conjugation may be a more defined structures. However, this assess-
ment is not always correct because CPP/nucleic acid covalent conjugates may 
also self-assemble into undefined nanostructures that could resemble non-cova-
lent complexes. This approach is also not rational for larger nucleic acid mole-
cules such as pDNA. 
Now we present a selection from the numerous reports of CPP mediated 
pDNA delivery into cells that have resulted in a significant biological effect. 
One interesting library of CPPs has been reported by Kichler et al., where syn-
thetic cationic amphipathic peptides have been modified with histidines [150]. It 
was shown already decades ago that using histidine mutations in a cationic 
peptide sequence can enhance gene transfection [151] and the main effect 
behind this is the pKa of the histidine imidazole group, which is ~6.0 and 
becomes cationic in a slightly acidic medium. Polyhistidines mediate an acid-
dependent fusion and leakage of negatively charged liposomes [152], [153]. At 
the physiological pH histidine alone is not able to condense pDNA efficiently, 
therefore, it requires an extra mechanism for DNA binding. A number of 
authors have found that the mere presence of histidines is not sufficient, as 
demonstrated previously for polylysines – a certain positioning of histidines is 
required to form the polar face of the peptide -helix [150]. The importance of 
the helical structure in DNA transfection was reported by Kuriyama et al., 
who obtained a 37 amino acid long peptide from human Factor VIII c-terminal 
domain to target phosphatidylserine, which is present in disturbed cellular mem-
branes such as in cancer cells [154]. The peptide sequence was mutated to 
increase similarity with cationic amphiphilic α-helical oligopeptides. A peptide 
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with the same amino acid composition, but with a scrambled sequence was used 
as a control to confirm that an -helical structure was not formed in the pres-
ence of membranes. The α-helical peptide was able to induce significant gene 
expression levels (comparable to the commercial gene delivery reagent, Lipo-
fectin), while the negative control remained at baseline levels.  
Another example of efficient pDNA delivery in cell culture was reported by 
Divita and colleagues, where they demonstrated that a hydrophobic fusion pep-
tide constructed from HIV-1, gp41, and the hydrophilic nuclear localization 
sequence of SV40 large T antigen, MPG, can efficiently deliver pDNA into 
cells [155]. This peptide predominantly binds pDNA by exploiting electrostatic 
forces, however these are not sufficient to form complexes at CR2, where posi-
tive charges are already in excess. These authors claim that for complete 
complexation a so-called peptide-cage is formed at higher peptide concentra-
tions and it is this cage that confers protection of the cargo molecule against 
enzymatic attack. Complexes with fully incorporated pDNA and a peptide cage 
are able to transfect cells and mediate gene expression comparable to LF2000. It 
is noteworthy that the gene expression obtained was not dependent on the pep-
tide concentration – both CR5 and CR20 provided similar levels of luciferase 
activity. Besides the induced reporter gene activity, complexes were able to 
deliver pDNA with the full-length encoding of antisense cDNA for human 
cdc25C, which led to an efficient decrease in the target protein and a resulting 
bioeffect.  
One common strategy to enhance the DNA binding ability of the peptide and 
form stable complexes is to introduce a hydrophobic moiety to the peptide 
sequence. Incorporation of an alkyl chain to the peptide mastoparan to obatin 
higher gene expression was evaluated already in 1999 [156]. By increasing 
lipophilicity, the authors were able to confer binding ability to mastoparan, 
which is otherwise unable to bind pDNA. The authors also showed that increas-
ing the hydrophobicity increased or stabilized the presence of -helical struc-
ture of the peptides and these peptides provide higher transfection. The benefit 
of incorporating a fatty acid into the peptide sequence has been shown in sev-
eral studies [137], [157], [158] that delivered nucleic acids. It has also been 
previously reported that adding stearic acid to the CPP improves complex for-
mation between CPP and nucleic acid and resulted in improved gene modula-
tion at a reduced peptide concentration [159], [160]. This effect was confirmed 
by pDNA delivery, where improved complex formulation and enhanced gene 
expression levels were observed [161].  
 
While CPPs have mainly been shown to be non-toxic [162], enzyme resistant, 
and provide efficient transfection in cell culture, their potential for in vivo 
delivery is s still under investigation. Many studies describe efficient in vivo 
pDNA delivery platforms, where CPPs have been utilized solely as a one 
moiety to increase cellular uptake. Several reports have shown that CPP can aid 
in local pDNA administration, yet, only a handful of works have achieved 
significant gene expression levels when systemically administering single-
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component CPP/pDNA complexes. An overview of some of these studies is 
provided in Table 2.  
CPPs have also been used as single-component systems to deliver siRNA in 
mice [163], [164]. Relatively efficient pDNA was achieved using either an 
intramuscular route [161] or using systemic administration [165], [166], [167]. 
The latter studies report the highest gene expression induction in lungs, with a 
profile very similar with other non-viral gene delivery reagents. In all of these 
studies a non-covalent complexation strategy has been used to form CPP and 
pDNA nanocomplexes. It is not entirely clear which properties from these 
nanocomplexes are responsible for efficient gene induction in vivo, however, 
the main parameters that determine the efficacy are probably the CPP sequence, 
the secondary structure it forms, membrane activity, nucleic acid condensation 
strength, physicochemical parameters, and stability against enzymatic digestion. 
Moreover, it has been shown for PEI [84], and recently for free polycations 
[168], that when non-covalent complexes form, the cationic delivery reagent is 
in excess and exists as a free fraction that is not incorporated into complexes 
with nucleic acids. This fraction is important for gene induction but also pos-
sibly mediates toxic side-effects. This makes the determination of parameters 
that are responsible for transfection efficacy even more difficult because 
delivery is not only mediated by the properties of the complexes that form, but 
possibly by the free cationic fraction and its properties. It is not clear if this 
could be the case for CPPs as well, but there are some indications that support 
this. Due to the multitude of possibilities, it is very difficult to optimize gene 





































































































































































































































































































































































































































































































































































1.3.4 Tuning specificity of CPPs 
As discussed above, CPPs are efficient delivery vectors that have a common 
property of being able to deliver macromolecular cargo into a very wide range 
of cells and tissues. This trait can be a drawback when developing delivery 
systems that target specific tissues or cell types. However, there are several 
strategies available to overcome this limitation – one of them is the activatable 
cell-penetrating peptide strategy (ACPP) developed and applied by R. Tsien et 
al. This technique is based on masking the cationic CPP's activity via an anionic 
peptide domain in a reversible manner [172]. This masking is detached via 
cleavage of protease-sensitive peptide linker that covalently conjugates the two 
domains together. Systemically administrating a masked conjugate does not 
induce any activity prior to deactivation. In his work Tsien has used enzyme 
sensitive activation of ACPP, which relies on matrix metalloproteinases 
(MMPs). These are enzymes that are needed to degrade extracellular matrix 
components during neoplastic growth and are therefore overexpressed in almost 
any types of tumor tissue [173]. When an MMP sensitive linker is cleaved, this 
leads to release of activated CPP with cargo molecule and enhanced cellular 
uptake [172]. Besides MMPs, other proteases has been harnessed using the 
ACPP strategy [174], [175].  
Tumor-targeting peptides also increase the specificity of CPP-mediated 
cargo delivery [176]. Phage display technology has significantly contributed to 
a major portion of tumor homing peptides, including Arg-Gly-Asp or RGD 
which has high affinity for integrins [177]. Since its discovery, this peptide 
sequence has been studied, modified, and used in many applications for targeted 
drug delivery to tumors [178]. One recent report by our group investigated CPP-
tumor homing peptide mediated drug delivery to glioma xenograft tumors. This 
study used phage-display technology to identify a glioblastoma homing peptide, 
gHo, which was further conjugated to a known CPP pVEC [179], [180]. How-
ever, targeting brain is considered one of the biggest challenges in the drug 
delivery field, due to the presence of the BBB, which is impermeable to the 
majority of therapeutics. Nevertheless, achievements have been made to aid 
delivery across the BBB. In one report, specific peptides are validated [181] and 
it has been confirmed, that one of these peptides, Angiopep-2 (ANG), crosses 
the BBB via receptor dependent transcytosis [182]. Its potential has been 




2. AIMS OF THE STUDY 
The main objective of the research presented in this dissertation is the develop-
ment of an efficient CPP vector for systemic gene delivery applications. Vari-
ous strategies were used to design peptides with improved usability for in vivo 
conditions and their delivery efficacy was studied in cell cultures, in vivo after 
systemic administration in both healthy and tumor-bearing mice. Specifically, 
the aims of this work are: 
 
 Paper I: The main aim was to establish the potential of PF14 to deliver 
pDNA into cells. For that, CPP and pDNA complexes were formed, 
characterized and their uptake rate into cells was evaluated. We estab-
lished the internalization route and then studied various aspects of 
induced bioactivity such as transfection rate in the presence of serum 
proteins, the percentage of transfected cells, and the toxicity profile. 
 
 Paper II: Here we aimed to study the potential of CPP-based delivery of 
pDNA across the blood-brain barrier. For that, we designed a range of 
CPPs, including PF14 analogs, that were based on using two BBB 
targeting peptide sequences – a glioma-homing peptide and angiopep-2. 
To assess their gene delivery potential, we exploited an in vitro model 
of the BBB.  
 
 Paper III: The aim here was to investigate the potential of PF14 to 
deliver pDNA and induce gene expression in different organs after sys-
temic administration via the tail vein. For this we investigated if 
PEGylation can be used to shield the efficient and unspecific transfec-
tion profile of PF14 and improve its in vivo usability. We went on to 
study the potential of PEGylated PF14/pDNA nanocomplexes to reach 
into tumors and then become activated via cleavage of the PEG by 
enzymes that are overexpressed in tumors. 
 
 Paper IV: Explore additional possibilities to further improve PF14 
mediated in vivo gene delivery as a suitable alternative to PEGylation. 
Optimization of complex formulation was studied varying CPP/pDNA 
doses and modifying PF14 fatty acid content and charge to investigate 
the influence of these parameters on complex formation, stability 
against enzymatic attack, membrane activity, transfection in cell culture 
and on gene delivery potential after systemic administration.  
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3. METHODOLOGICAL CONSIDERATIONS 
3.1 Peptide modification 
All the peptide sequences that were studied in this dissertation are presented in 
Table 3. All of these are based on the PF14 peptide, which was first established 
by Ezzat et al. [186] to deliver ONs and is now further modified to achieve 
improved potential for gene delivery for in vivo applications. 
In Paper I, we evaluated the potential of PF14 for pDNA transfection. For 
that, this peptide was non-covalently mixed with nucleic acid and resulted in the 
formation of nano-sized complexes that are taken up by cells via endocytosis, 
using scavenger receptors. At the same time nsPF14 (PF150), which lacks the 
N-terminal fatty acid modification, was not able to form sufficiently stable com-
plexes. PF14 was able to induce significant gene expression levels in different 
cell-lines. 
In Paper II, we studied the potential of CPP-based delivery of pDNA across 
the BBB. For that, we constructed a range of CPPs using two targeting 
sequences – glioma-homing peptide [179] and angiopep-2 [181] to target the 
BBB. gHo was conjugated to PF14, TP10 [187], stearyl-TP10 (PepFect3, PF3), 
PF28, SynB3 [188], [189] and stearyl-SynB3, to obtain PF31, PF33, PF34, 
PF35, PF36, and PF37, respectively. ANG was conjugated to a truncated PF14, 
resulting PF32. Both of these targeting peptides were conjugated to CPPs  
C-terminally.  
To assess their gene delivery potential, we exploited an in vitro model for 
BBB.  
In Paper III, after having established that PF14 is able to deliver pDNA effi-
ciently in cell culture, we evaluated its transport potential in vivo, after systemic 
administration. This lead to the induction of significant gene expression in 
different tissues such as lungs, liver, and spleen. However, this efficient gene 
delivery is associated with acute side-effects and, therefore, we conclude that 
this delivery vector needs improvement. PEGylation has improved the proper-
ties of a wide variety of therapeutic molecules, and is also able to act as a 
biologically inert shield to sterically protect nanoparticles against unwanted 
interactions [190]. To apply this strategy, a series of PEGylated peptides 
(PF141-PF143) were designed followed by an assessment of their ability to 
form complexes and transfect cells. These peptides were able to completely 
mask the transfection potential of PF14. To restore the PF14 mediated transfec-
tion, peptides were PEGylated via a cleavable linker, which enables specific 
activation of complexes in tumor tissues. For this we exploited the MMP activa-
tion strategy, first presented by R. Tsien's group [172]. PEGylation was conju-
gated to peptides via an MMP enzyme specific cleavage site that consists of six 
amino acids (PF144-PF146). As a control, we used scrambled sequence that 
contained the same amino acid (PF147-PF149) 
In Paper IV, we studied the formulation of PF14 based transfection com-
plexes for the purpose of reducing previously reported side-effects in vivo. First, 
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we either decreased the charge by substituting Orn10 with Glu10 or increased 
the charge by substituting Ala15 and Ala16 with ornithines. These resulted in 
the peptides PF1451 and PF1450, respectively. Increasing the charge should 
enable one to decrease the concentration of peptide required to complex the 
same amount of nucleic acids. As a control we used PF6 which has been 
reported to have a high cationic charge density [191] Next, we either reduced 
(PF155) or decreased (PF161) the fatty acid length to determine if this property 
can influence the complexation and stability of peptide/pDNA complexes under 
in vivo conditions.  
 
 
3.2 Peptide synthesis 
All peptides used in this dissertation (Table 3) were synthesized using a solid-
phase peptide synthesis (SPPS) strategy first introduced by Bruce Merrifield in 
1963. This technique is based on the stepwise addition of protected amino acids 
to a growing peptide chain which is covalently linked to a solid phase resin 
[192]. In this work, synthesis of peptides was carried out using an automated 
peptide synthesizer using standard protocols for Fmoc solid-phase synthesis. 
We used rink-amide MBHA resin as a solid phase to obtain C-terminally ami-
dated peptides. N-terminally stearylated peptides were prepared by treatment of 
peptidyl resin with 4 equiv. of stearic acid, 4 equiv. of HOBt/HBTU, and 8 
equiv. of DIEA in DMF/DCM for 18 h. C-terminally PEGylated peptides were 
prepared by treatment of Rink-amide MBHA resin with 2 equiv. of Fmoc-
PEGn-CH2CH2COOH, 2 equiv. of HOBt/HBTU and 4 equiv. of DIEA in 
DMF/DCM for 24 h which was followed by standard Fmoc peptide synthesis. 
The final cleavage of peptide chains from resin was performed using a 95% 
trifluoroacetic acid (TFA)/2.5% TIS/2.5% water for 2 h, at RT. Peptides were 
purified using a high-performance liquid chromatography (HPLC) using a 
5−80% acetonitrile (0.1% TFA) gradient. The molecular weight of the peptides 
was analyzed by matrix-assisted laser desorption-ionization time-of-flight 
(MALDI-TOF) mass spectroscopy and the purity of each was >90%, as deter-
mined by analytical HPLC. 
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Table 3. Sequences used in thesis 
CPP Sequence  Reference 
PF14 Stearyl-AGYLLGKLLOOLAAAALOOL-NH2 [186],[193] 
PF31 Stearyl-AGYLLGKLLOOLAAAALOOLNHQQQNPHQPPM-NH2 [194] 
PF32 Stearyl-LLOOLAAAALOOLTFFYGGSRGKRNNFKTEEY-NH2 [194] 
PF33 AGYLLGKINLKALAALAKKILNHQQQNPHQPPM-NH2 [194] 
PF34 Stearyl-AGYLLGKINLKALAALAKKILNHQQQNPHQPPM-NH2 [194] 
PF35 Stearyl-WLKLWKKWLKLWNHQQQNPHQPPM-NH2 [194] 
PF36 RRLSYSRRRFNHQQQNPHQPPM-NH2 [194] 
PF37 Stearyl-RRLSYSRRRFNHQQQNPHQPPM-NH2 [194] 
PF141 Stearyl-LLOOLAAAALOOLL-X-PEG600 [167] 
PF142 Stearyl-AGYLLGKLLOOLAAAALOOLL-X-PEG1000 [167] 
PF143 Stearyl-AGYLLGKLLOOLAAAALOOLL-X-PEG2000 [167] 
PF144 Stearyl-AGYLLGKLLOOLAAAALOOLL-X-PLGLAG-PEG600 [167] 
PF145 Stearyl-AGYLLGKLLOOLAAAALOOLL-X-PLGLAG-PEG1000 [167] 
PF146 Stearyl-AGYLLGKLLOOLAAAALOOLL-X-PLGLAG-PEG2000 [167] 
PF147 Stearyl-AGYLLGKLLOOLAAAALOOLL-X-LALGPG-PEG600 [167] 
PF148 Stearyl-AGYLLGKLLOOLAAAALOOLL-X-LALGPG-PEG1000 [167] 
PF149 Stearyl-AGYLLGKLLOOLAAAALOOLL-X-LALGPG-PEG2000 [167] 
PF150 AGYLLGKLLOOLAAAALOOL-NH2 [186],[193] 
PF155 Decanyl-AGYLLGKLLOOLAAAALOOL-NH2  
PF161 Behenyl-AGYLLGKLLOOLAAAALOOL-NH2  
PF1450 Stearyl-AGYLLGKLLOOLAOOALOOL-NH2  
PF1451 Stearyl-AGYLLGKLLEOLAAAALOOL-NH2  
PF6 Stearyl-AGYLLGKaINLKALAALAKKIL-NH2 [164]  
PF, PepFect; Stearyl, stearic acid; decanyl, decanylic acid; behenyl, behenylic acid; X, 6-
aminohexanoic acid. 
a four trifluoromethylquinoline moieties attached to succinylated lysine tree. 
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3.3 Complex formulation strategies 
3.3.1 Non-covalent formulation strategy 
There are two main strategies to form complexes between a peptide and its 
cargo: covalent conjugation and non-covalent formulation. The latter is benefi-
cial for nucleic acids due to their negative net charge, which bind to cationic 
CPPs. Non-covalent complex formulation methods has been used to complex 
various peptides with nucleic acids, including pDNA [195], [135]. Besides 
electrostatic forces, complex formation and pDNA condensation is supported by 
hydrophobic interactions of peptide molecules which are able to increase pep-
tide-mediated gene delivery [137], [159], [160]. 
Throughout the work presented in this dissertation, we have used non-cova-
lent complex formation with the luciferase and EGFP encoding plasmids, 
pGL3, pLuc2, and pEGFP-C1, which were mixed with CPPs at different 
pDNA-to-peptide CRs, which were calculated theoretically, taking into account 
the positive charges of the peptide and negative charges of the pDNA. For in 
vivo studies, higher dose of pLuc2 (20 μg, if not indicated otherwise) was mixed 
with peptide at CR2 or CR4 in MQ water and the volume of complexes was 
kept constantly 100 μl. All complexes were incubated at room temperature (RT) 
for 40 minutes prior to their use in subsequent assays. Immediately before sys-
temic administration, glucose was added to complexes to achieve an isotonic 
injection solution (5%) and injected. 
 
 
3.3.2 Modification of PEGylation rate  
In Paper III, to achieve tunable PEGylation, complexes were formed by varying the 
PEGylation rate which is defined as the amount of PF14 which is substituted with 
its PEGylated PF14 analogue. For example, a PEGylation rate of 20% represents 
complexes with 80% of PF14 and 20% corresponds to PEGylated PF14 analogue. 
To achieve this, PEGylated peptides were first mixed with pDNA followed by the 
addition of PF14 and incubation for 40 minutes at room temperature.  
 
 
3.4 Characterization of formed complexes 
We characterized the peptide/pDNA complexes using four different methods in 
parallel. Initially, the ability of cationic CPP to bind and neutralize pDNA was 
assessed with gel shift assay, the pDNA condensation rate was determined by 
an ethidium bromide (EtBr) exclusion assay. Both of these characterize inter-
actions with pDNA but do not show if indeed nano-sized complexes are formed. 
To verify this, we used dynamic light scattering (DLS) to measure the hydro-
dynamic diameter in aqueous solution as well as the zeta potential of the pre-
formed complexes. Last, but not least, we used a heparin displacement assay to 
compare the stability of the complexes.  
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3.4.1 DNA binding and condensation 
DNA binding was first assessed using a gel retardation assay that is able to 
detect if the complexes that form are too large to migrate through agarose gel. If 
complete DNA binding occurs and complexes are formed, nucleic acid can be 
detected in the well, however, in the case of incomplete complexation a free 
fraction of pDNA able to migrate into the gel.  
We analyzed the rate of DNA condensation by peptides using an EtBr exclu-
sion assay. This assay is based on the ability of EtBr to interact with nucleic 
acids, and results in an increase of fluorescence. When pDNA is efficiently 
condensed, then interactions with EtBr are limited, which results in quenching 
of pDNA fluorescence.  
 
 
3.4.2 Complex size and surface charge 
To study the physicochemical parameters of CPP/pDNA complexes such as size 
and surface charge (zeta potential), we carried out DLS measurements using a 
Zetasizer Nano ZS apparatus. The DLS detects the size of particles from 
fluctuations in scattered light intensity due to the Brownian movement of the 
measured particles. This is a commonly applied technique to measure the aver-
age size of particles present in a solution [196].  
Each charged particle in solution surrounded by an electrical double layer of 
ions and counter-ions. The potential that exists at this hydrodynamic boundary 
is known as the zeta potential – it is determined by electrophoresis of the 
sample and measuring the velocity of the particles using laser Doppler 
velocimetry [197]. The surface charge of the particles, together with its size, can 
determine not only its transfection ability, but also the biodistribution between 
tissues, and eventually, in vivo fate.  
 
 
3.4.3 Heparin displacement assay 
The heparin displacement assay we used is based on the ability of negatively 
charged heparin molecules to interact with positively charged cationic vector 
and displace the negatively charged pDNA from complexes. The concentration 
of heparin required to displace pDNA indicates the strength of CPP/pDNA 
complexes and can be monitored by either gel shift or an EtBr exclusion assay. 
 
 
3.5 Cell cultures 
The majority of cell-lines used in thesis (Table 4) are commonly utilized to 
study gene delivery potential of different vectors. The main optimization and 
bioactivity studies throughout this thesis have been made in CHO cells, how-
ever, it is essential to assess gene delivery efficacy in a variety of cell-lines 
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because transfection properties can vary depending on the cell-line type and its 
origin. In total, we used eleven different cell-lines that originate from human 
tissues or mus musculus, being cancer or non-cancer cell-lines. All cells were 
cultured at 37°C, 5% CO2 under a humidified environment with suitable media, 
supplemented with nutrients and antibiotics.  
 
 
Table 4. Cell-lines used in thesis 
Cell-line name Application Paper  
HEK239 Human embryonic kidney cells pDNA delivery efficiency I 
HT1080 Human fibrosarcoma cells pDNA delivery efficiency IV 
U2OS Human osteosarcoma cells pDNA delivery efficiency I 
U87 Human glioblastoma cells pDNA delivery, tumor 
induction 
I, II, III 
THP1 Human monocytic cells Evaluation of immune 
response induced by CPPs 
and their complexes 
I 
RD4 Human rhabdomyosarcoma cells pDNA delivery efficiency I 
CHO Chinese hamster ovary cells pDNA delivery efficiency, 
uptake studies, toxicity 
evaluation 
I, III, IV 
MEF Mouse embryonic fibroblasts pDNA delivery efficiency I 
mES Mouse embryonic stem cells  pDNA delivery efficiency I 
N2a 
 
Mouse neuroblastoma cells pDNA delivery efficiency, 
tumor induction, 
III 





3.6 Bioactivity of CPP/pDNA complexes in cell culture 
3.6.1 Receptor dependent uptake and endosomal escape  
We analyzed the intracellular delivery and uptake mechanism for PF14/pDNA 
complexes in Paper I using CHO cells (Table 4). Scavenger receptor mediated 
endocytosis was shown to be a prominent uptake mechanism for PF14/ON 
nanoparticles [146]. Furthermore, the affinity of this receptor to bind poly-
anionic ligands has been shown earlier [198]. The effect of inhibiting scavenger 
receptors on the transfection efficacy of PF14 was evaluated using the specific 
inhibitory ligands, polyinosinic acid, fucoidan, and dextran sulfate. As a nega-
tive control, we used three structurally similar molecules that have no affinity 
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against receptors under the same experimental conditions: poly C, galactose, 
and chondroitin sulfate [146], [198], [199]. These results were corroborated 
using transmission electron microscopy, where we determined the intracellular 
localization of Nano-gold labelled pDNA complexed with PF14.  
The extent of endosomal entrapment was evaluated using the endosomo-
tropic agent chloroquine CQ in Papers I and IV, which acts as a weak base and 
adsorbs protons. This property inhibits acidification of endosomal compart-
ments and results in the swelling and rupture of endosomes [200]. This leads to 
the release of endosomal content, including complexes, into the cytosol and an 
increase in transfection efficiency which could indicate the proportion of com-
plexes entrapped in endosomes 
 
 
3.6.2 Evaluation of gene delivery efficiency  
The gene delivery efficiency of PF14/pDNA complexes was initially evaluated 
in Paper I. To characterize the transfection profile in vitro, we exploited differ-
ent experimental strategies. We assessed the impact of the presence of serum 
proteins on transfection efficiency and evaluated the decay kinetics by 
analyzing the luciferase activity after PF14/pGL3 transfection at different time 
points (4–72 hours). To assess the ability of PF14 complexes to transfect the 
cell population at different confluences, an increasing range of cells were trans-
fected, and the luciferase activity was measured. The delivery efficacy rate in 
the cell population was evaluated by delivering an EGFP encoding plasmid 
(pEGFP-C1) and measuring its expression in the cell population using fluores-
cence-activated cell sorting (FACS) analysis.  
 
 
3.6.3 Toxicity profile and induction of innate immunity  
To analyze the impact of peptide mediated transfection on the viability of cells, 
we used a colorimetric MTS cell viability assay in Papers I and III and a WST-1 
cell proliferation assay in Paper II. These analyzes enable one to detect changes 
in the metabolic activity of cells after transfection and are based on mitochon-
drial dehydrogenases that reduce tetrazolium into a colored formazan product 
which is proportional to the number of viable cells. 
A human acute monocytic leukemia cell-line (THP-1) was used as a model 
system for immune response studies in vitro because they are capable of 
producing cytokines IL-1 and TNF-a when differentiated into macrophage-like 
cells. They were used earlier to study the induction of immune response by 
CPPs and their complexes with nucleic acids [162]. In Paper I, IL-1 production 






3.6.4 Gene delivery potential of CPP/pDNA  
complexes in vitro BBB model 
To study the transport potential of CPPs over BBB, we used a Transwell™ 
apparatus. This consists of two compartments. The first is an apical compart-
ment with a semi-permeable insert representing the blood site. This is where 
brain endothelial bEnd.3 cells were cultured. In the lower chamber we cultured 
glioblastoma U87 cells. All experiments were performed on bEnd.3 cell mono-
layer 10–14 days after cell seeding for the transfection assay. The media was 
changed in both the upper and lower chambers every 2–3 days. U87 cells were 
separately seeded and the experiments were carried out 3–4 days after seeding. 
On the day of each experiment, the bEnd.3 cell monolayers grown on semi-
permeable inserts were placed on U87 seeded wells and transfected. Two hours 
after transfecting bEnd.3 cells, all inserts were removed from U87 wells and 




3.7 Evaluation of CPP/pDNA complex  
interactions with blood components 
The first interactions of any therapeutics after systemic administration occurs 
with blood components. Therefore, we evaluated interactions of complexes with 
different components such as RBCs, serum, and also more specific degradation 




RBCs possess negative zeta potential, which is contributed by molecules on the 
cell surface that have the negative charge [61] and therefore these are one of the 
first cells that have possibility to interact with positively charged complexes in 
the bloodstream. As a measure of membrane activity and toxicity, we analyzed 
the hemolytic activity of both naked CPPs and CPP/pDNA complexes in Paper 
IV using a 2% mouse RBC solution. We expressed the results as the concentra-




3.7.2 Serum incubation 
To evaluate the impact of serum on the size of complexes or their zeta potential 
and transfection efficiency, we incubated complexes with fetal bovine serum 
(FBS) and carried out either a gel shift assay, measured their size and surface 
charge or transfected cells after incubation of complexes in FBS.  
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3.7.3 Stability against enzymatic attack 
One requirement for gene delivery vectors is their ability to protect their cargo 
from degradative enzymes such as nucleases. Delivery vectors should also be 
sufficiently stable against proteinase digestion. To assess these parameters, 
CPP/pDNA complexes were treated with DNase I and Proteinase K and further 
analyzed using either a gel shift assay, EtBr exclusion, or transfection with 
enzyme-treated complexes.  
 
 
3.8 In vivo bioactivity of systemically  
administered CPP/pDNA complexes 
All animal experiments and procedures presented in this dissertation were 
approved by the Estonian Laboratory Animal Ethics Committee (approval nos. 
69 and 70, dated Feb 9, 2011). 
 
 
3.8.1 Induction of tumor models 
To analyze the biodistribution of CPP/pDNA complexes or their induced gene 
expression in tumors, we used subcutanous (s.c.) tumor models. We induced 
mouse Neuro2a tumors in BALB/c mice. Human tumor xenografts were 
induced in nude animals (Hsd: Athymic Nude-Foxn1nu female, 4–6 week old). 
The tumors were induced by resuspending 1 × 106 cells in 100 μl volume of ice-
cold DMEM without any supplements. The xenografting was performed by 
implanting the cell suspension subcutaneously to the right flank. Upon the 
appearance of tumor growth, (tumor size of approximately 100 mm3), mice 
were injected i.v. (via tail vein) with the peptide/pDNA complexes. 
 
 
3.8.2 Biodistribution  
The availability of complexes was determined 24 hours after administration. For 
that, PF14 and PEGylated PF14 peptides were complexed with Cy5-labelled 
pDNA. Complexes were administered i.v. via tail vein. After 24 hours, the mice 
were sacrificed and their tissues were collected and subjected to a homogeni-
zation protocol (provided in paragraph 3.8.4). We measured the fluorescence of 
Cy5-labelled pDNA within the tissue homogenates using a Spectra Max Gemini 
XS fluorometer. Three technical replicates were combined to find an average 
FU (fluorescence unit). The average FU values within each sample were 






3.8.3 Pharmacokinetic profile 
The stability of complexes in blood was studied using Cy5-labelled pDNA, 
which was mixed with the peptides and injected as described above. Blood was 
collected at different time points (0.5 h–6 h) from the saphenous vein and its 
fluorescence was measured. For data analysis, the fluorescence of the untreated 
samples was subtracted from the other samples. The resulting fluorescence 
values were normalized to the pDNA concentration which was determined 
using either naked pDNA or peptide/pDNA complex calibration curves. 
 
 
3.8.4 Gene expression induction in different tissues 
Throughout Papers III and IV, we measured luciferase gene expression in 
different tissues. For that, 24 hours after administration of complexes, mice 
were sacrificed using cervical dislocation, their organs were harvested and snap-
frozen on dry ice. The tissues were homogenized using a Precellys®24-Dual 
homogenization system and lysed using 1 × Promega lysis buffer. The lucif-
erase content was analyzed as described previously [201]. Briefly, homogenized 
tissues were thawed and 500 μl of Promega Reporter lysis 1 × buffer was added. 
The samples were subsequently vortexed for 15 minutes, subjected to 3 
consecutive freeze–thaw cycles (liquid nitrogen and 37 °C water bath), centri-
fuged for 3 min at 10 000 g, at 4 °C; followed by the removal of supernatant, 
which was saved for later analysis. Thereafter, 500 μl of lysis buffer was again 
added to the pellet and the extraction process repeated (without freeze – thaw 
cycles). The second supernatant was combined with the first one and was sub-
jected to luciferase activity or for fluorescence measurements. After measuring 
luciferase, the obtained LUs (light unit) out of three technical replicates was 
normalized to the protein content and the resultant RLU/mg were normalized to 





4. RESULTS AND DISCUSSION 
4.1 Characterization of PF14 mediated  
gene delivery in cell culture (Paper I) 
Our group has recently designed a new series of modified CPPs, PepFects, that 
have been shown to be efficient for the delivery of various nucleic acids [161], 
[186], [164],[202], [203]. Their shared properties, such as having a conjugated 
fatty acid moiety and cationic charge makes them good vectors to bind and 
condense nucleic acids into complexes (Figure 2 and 3). The main focus of the 
research presented here, was to determine whether PF14, which has previously 
been shown to be an efficient delivery vehicle for SCO [186] and siRNAs 
[146], could be utilized to deliver pDNA into cells.  
First, we analyzed the ability of PF14 to form complexes with pDNA and it 
became clear that this peptide can indeed bind and condense pDNA into com-
plexes that are relatively stable in the presence of a negatively charged competi-
tor molecule, heparin. DLS measurements revealed that the average size of 
these complexes is between 130–180 nm and they possess a negative surface 
charge. In comparison, nsPF14, which lacks stearic acid modification, can also 
condense pDNA with a similar efficiency; however, the heparin displacement 
assay revealed that nsPF14 creates weaker complexes.  
After confirming effective nanoparticle formation, we moved on to study the 
transfection efficacy of both peptides using a luciferase encoding plasmid DNA, 
pGL3. Complexes made with PF14 provide high luciferase levels in CHO cells, 
while nsPF14 complexes are not able to induce any gene expression (Figure 3). 
This was explained with uptake studies which revealed that nsPF14 is unable to 
deliver fluorescently labelled pDNA into cells over a range of CRs, yet PF14 is 
able to deliver pDNA into cells in a dose dependent manner. We propose that 
nsPF14 forms unstable complexes that dissociate before they can be taken up by 
cells. It has been shown that the delivery properties of different CPPs for 
oligonucleotides can be significantly improved when conjugated with fatty 
acids [204].  
The potential of PF14 to deliver pDNA was studied in a variety of different 
cell-lines, including cancer and non-cancer cells. We found that PF14 com-
plexes induce gene expression with similar efficacy as a commercial and com-
monly used cationic lipid based transfection reagent Lipofectamine™ 2000 
(LF2000). Moreover, we observed significant gene expression in cell-lines that 
are considered relatively refractory to chemical transfection reagents. The gene 
expression was again comparable with LF2000.  
The first indication that endocytotic pathways are utilized in the uptake of 
PF14/pDNA complexes came from the experiment where CQ incubation 
increased the transfection efficacy of PF14 complexes 10 fold. Endocytosis is 
commonly recognized as an main cellular entry route during CPP/cargo deliv-
ery, however, it is also agreed that the biggest intracellular bottleneck in this 
entry route is endosomal escape [205]. We used transmission electron micros-
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copy to verify that endocytosis occurs, and these results indicate that caveolae-
mediated endocytosis is the dominant entry route. Caveolar uptake has previ-
ously been shown to be involved in the cellular delivery of proteins by TP10, 
the predecessor peptide of PepFects [206]. Based on a previous report that the 
uptake of PF14/ON nanocomplexes are dependent on class A scavenger recep-
tors (SCARA) [146], the inhibition of certain SCARA subtypes significantly 
decreased the delivery and expression of PF14/pDNA complexes. This suggests 
that this receptor mediates the uptake of PF14/pDNA nanoparticles via caveo-
lae-mediated endocytosis. This is in line with reports that SCARAs are internal-
ized via caveolae dependent endocytosis in macrophages [207]. Furthermore, 
SCARAs are associated with the uptake of negatively charged molecules [198], 
[199].  
Regarding PF14 mediated gene delivery, one important feature is its ability 
to transfect a large population of cells in the presence of serum, which also does 
not significantly reduce gene expression. Complexes made with this peptide 
provide improved delivery efficiency compared with its predecessor, PF3. It is 
also noteworthy that PF14-mediated delivery and its efficiency are not associ-
ated with toxic side effects as assessed using the in vitro toxicity and 
immunogenicity assays. Taken together, this conclusively makes PF14 an effi-




Figure 3. Noncovalent Pepfect14 and pDNA complexes mediate efficient gene delivery 
into cultured cells 
 
 
4.2 CPP-based delivery of pDNA across  
the blood–brain barrier (Paper II) 
In this study, we used a series of CPPs, including PF14 and its analogs, to 
deliver pDNA to brain cells in an in vitro BBB model (Figure 4). PF14 was 
conjugated with two different targeting peptides, including a glioma-homing 
peptide (gHo). The gHo peptide was identified as a glioma-specific homing 
peptide via an in vitro phage display technology and has previously been used 
as a targeting moiety in a glioma xenograft mouse model [179]. The other pep-
tide conjugated with PF14 was angiopep-2 (ANG), which was derived from the 
Kunitz domains of aprotinin, a protease inhibitor, and this peptide may be a key 
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to unlocking receptor-mediated transport into the brain because ANG has previ-
ously been observed to demonstrate transcytosis via the low-density lipoprotein 
receptor-related protein 1 (LRP1) receptors on the BBB which results in its 
endocytosis into glioma cells via their LRP receptors [181], [183]. For refer-
ence, we present synthesized peptides in table 3.  
In this BBB model, transfection was achieved by PF14 and its analogs, PF31 
and PF32. PF31 carried the gHo targeting sequence, while PF32 is a truncated 
version of PF14 together with the ANG sequence. PF32 induced two times 
higher gene expression over PF14, and was the most successful candidate in this 
study (Figure 4). DLS measurements for PF32 and PF14 confirmed that both 
condense pDNA into nano-sized particles at CR2 and 3 with complex sizes 
ranging between 120–180 nm and with slightly negative or neutral surface 
charge. Both of these peptides were able to transfect cell-lines used in BBB 
model, the Transwell system, separately as well, however, PF32 delivered 
pDNA more efficiently in the bEend3 cell-line than the PF14 peptide. It also 
exhibited better gene induction in U87 cells in the Transwell system as well. 
Taken together, PF14 has potential to be modified with homing peptides with-
out significantly compromising its delivery efficacy. Furthermore, PF14 and its 





Figure 4. PF14 or PF14 modified with targeting peptide sequence are both efficient in 




4.3 PF14 gene delivery potential and its  
improvements for in vivo applications (Paper III) 
After confirming that PF14 is able to deliver pDNA, we proceeded to evaluate 
its potential to deliver genes under in vivo conditions. To assess this, PF14 was 
complexed with luciferase encoding pDNA (20 g) and administered systemi-
cally via intravenous (i.v.) injection. PF14-mediated gene delivery induces 
luciferase expression in various organs, particularly in lungs, where luciferase 
levels reach up to 3 logs over control (naked pDNA levels). We went on to 
compare this expression with other CPPs and found that the delivery efficacy 
stayed in line with ppTG1 (Table 2), however, PF14 was able to achieve the 
same gene expression levels with a significantly lower dose of pDNA (20 g vs. 
50 g). However, we also observed an occasional toxic event, where one animal 
out of fifteen died after minutes. This result highlights the need to further opti-
mize PF14 mediate gene delivery for improved in vivo use.  
PEGylation has been shown to mask the delivery activity of CPP [190], and 
is able to enhance the half-life of therapeutic molecules in the bloodstream by 
reducing interactions with blood-stream components. PEGylation also enhances 
passive tumor targeting [208]. To study the effect of PEGylation on gene deliv-
ery, we created PF14 analogues with C-terminally attached PEG molecules that 
had different molecular weights (600, 1000, and 2000, for PF141, PF142 and 
PF143, respectively). Their sequences are provided in table 3. First, we per-
formed experiments to test if PF14 is still able to complex pDNA after 
PEGylation. We found that PF141 and PF143 were able to complex pDNA, but 
PF142 does not efficiently form complexes and requires higher concentrations 
for that. We then tested if PEGylated complexes are able to transfect cells and 
found that this ability was abolished, which suggests overly efficient masking 
by the PEG molecule.  
We hypothesized that more favorable complex properties could be achieved 
with complexes formed with an optimal amount of PEG. To study this, we 
titrated the amount of PEGylated peptide in the complexes and studied both 
complex formation and their transfection ability. To describe the amount of 
PEGylated peptide within the complexes, we introduce the term PEGylation 
rate, which is defined as the amount of PF14 that is substituted with its 
PEGylated analog. For example, a PEGylation rate of 20% means that 20% of 
the cationic charges arise from the PEGylated peptide. Generally, the more 
PEGylated a peptide was, the lower was transfection ability of complexes. The 
size for all these complexes remained between 100–200 nm and displayed a 
positive surface charge 
We also tested the biodistribution of complexes 24h after systemic 
administration and it was seen that PEGylation reduced the accumulation of 
complexes in lungs, compared with PF14/pDNA complexes. Moreover, 
PEGylated complexes remain in the blood stream longer than unmodified PF14, 
which probably interacted more with different components and tissues. When 
analyzing gene induction by PEGylated complexes in liver and lung, it became 
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evident that gene expression decreases with increasing PEGylation rate. More-
over, even at low PEGylation rates, these complexes are able to induce gene 
expression in tumors (but luciferase activity was still detected in lungs and 
liver).  
In order to achieve tumor tissue specific gene delivery, we used a strategy 
reported earlier by Tsien [172], where tumor specific CPP activation is achieved 
via cleavage of a deactivating moiety, which in this work is represented by the 
PEG molecule (Table 3, Figure 5). The PEG is conjugated to the PF14 via short 
peptide sequence, that is substrate for MMP enzyme, which is overexpressed in 
tumors. Once the complex reaches in tumors, the PEG molecule can be cleaved, 
thereby restoring the ability to transfect cells. However, if the PEG shell is too 
dense, it might prevent interactions between the enzyme and its cleavage site. 
At the other extreme, complexes made with PF14 analogues with low 
PEGylation rates do not completely deactivate the complex. To find a suitable 
PEGylation rate, we evaluated complexes made with an increasing PEGylation 
rate in cell culture, where complexes were pretreated with MMP enzyme. We 
confirmed that complexes treated with the enzyme were able to induce gene 
expression, while complexes without MMP treatment and complexes made with 
an uncleavable control peptide induced gene expression only at a moderate 
level. The titration of PEGylation in complexes did not hinder MMP enzyme 
activity, at least not at the concentrations we tested, which is presumably much 
higher than that found in tumor tissues. We then proceeded to test how 
PEGylated PF14 complexes behave in vivo. For this, we evaluated the gene 
delivery potential of differently PEGylated complexes in mice bearing subcuta-
nous Neuro2a tumors. Although gene expression was induced in tumors already 
at lower PEGylation rates, in this case the transgene was also delivered to lung 
tissue. At higher PEGylation rates, gene expression was not observed in any 
other tissue aside from the tumors. The most optimal gene expression was 
achieved with PF144, which has a smaller sized PEG and a PEGylation rate of 
70%. PF144 provides the highest and the most specific gene induction. It is also 
noteworthy that none of the animals that received PEGylated complexes were 
observed to experience acute toxic effects. In conclusion, this strategy repre-




Figure 5. The complexation scheme of PEGylated MMP sensitive peptide/pDNA com-
plex formation [167]. 
 
 
4.4 Formulation characteristics governing  
PF14 gene delivery in vivo (Paper IV) 
This research addresses various parameters that can potentially influence the 
ability of CPP/pDNA complexes to transfect cells in vivo. In our previous work 
we observed occasional acute toxic effects associated with PF14 mediated gene 
delivery. We explored PEGylation as a potential solution, but found that this 
altered the transfection process itself. Knowing that the toxicity of cationic 
polymers are directly associated with the free fraction of polymer that is not 
bound to the DNA [84], [168], we hypothesized that toxic side-effects can be 
mitigated by increasing the amount of negatively charged nucleic acids in PF14 
complexes (Figure 6). 
DLS measurements revealed that increasing the nucleic acid concentration 
results in a sharp decrease in the surface charge. This indicates an absence of 
free peptide to supplement the positive surface charge. We assessed toxicity 
using hemolysis instead of more common in vitro toxicity assays because RBCs 
are one of the first cells that can interact with systemically administered com-
plexes. Furthermore, hemolysis can indicate high membrane activity of CPP 
and its respective complexes. For PF14, the concentration needed to lyse 50% 
of cells (HC50) in this experimental setup was 0.66 M. Adding nucleic acid 
increased the HC50 by about two fold, which indicates that a fraction of the 
peptide is complexed with pDNA which results in a reduction of hemolysis. 
Transfecting cells with complexes made at three increasing CRs clearly indi-
cated that the excessive peptide concentration does not increase gene induction. 
Controversially, potential cytotoxicity can occur. This also applies for in vivo 
gene delivery, where complexes made at CR2 with high pDNA doses (50g) 
induce high, almost comparable transgene expression with the parent formula-
tion (CR4 and 20 g) but do not induce any occasional lethal effects. This was 
also corroborated by biodistribution studies, where optimized complexes dis-
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played reduced accumulation in liver and lungs and accumulated more in blad-
der compared with the parent formulation. This reduced accumulation in lung 
tissues also occurred with PEGylated complexes, which highlight the possibility 
of using an optimized formulation as a good alternative to PEGylation (Figure 6). 
To further investigate the possibility of reducing the free peptide fraction in 
the complexes, we synthesized several PF14 analogs (Table 3), with either an 
increased (PF1450) or decreased (PF1451) charge, or where the length of fatty 
acid chain had been shortened (PF155) or extended (PF161). We used PF6 as a 
control because it is a highly charged peptide at neutral pH [191]. All of these 
peptides, including the positive control Jet-PEI, were able to complex and con-
dense pDNA, transfect it into cells at moderate (PF1451 and PF155) to high 
levels (PF1450, PF161, and PF6). Both peptides with a high charge content 
induced higher gene expression than PF14, while PF161 remained at the same 
level. All of these peptides formed nano-sized complexes, and typically had a 
positive surface charge. We observed that the surface charge was influenced 
more by the presence and length of the fatty acid. We also observed that the zeta 
potential increases with an increase in alkyl chain length. Next, we evaluated 
how well complexes made with these peptides provided protection against 
different enzymatic treatments. First, we observed that peptides with higher 
charge provided better DNA protection when subjected to DNAse attack. 
Proteinase K, which degrades the peptide was completely inefficient to degrade 
PF6 complexes, followed by PF161, PF14 and PF1450. PF6 also had reduced 
hemolytic activity, while other peptides stayed in a similar range with each 
other. When adding pDNA to complexes, the peptides with lower charge con-
tent were more tightly bound to complexes and their HC50 increased. This indi-
cates the importance of the free peptide concentration. 
When delivering pDNA systemically using these peptides, both PF161 and 
PF1450 were able to induce gene expression in liver and lungs, PF161 even 
provided similar levels as PF14. Intriguingly, PF6, which displayed excellent 
gene transfer activity in cell culture, was stable against enzymatic attack and 
displayed reduced hemolysis, was, nonetheless, also not able to induce any gene 
expression. PF1455, which has the highest membrane activity, also did not 
induce gene expression. We found that increased charge content and sufficient 
fatty acid length are both factors that simultaneously contribute to the stability 
of these complexes against enzymes, transfection in cell culture, and for suffi-
cient membrane activity. Taken together, these parameters ought to be consid-




Figure 6. We suggest that, depending on the concentrations used, CPP/pDNA com-
plexes can have a high concentration of free peptide, which can result in excess mem-
brane activity or acute toxic effects. Increasing the pDNA dose enables it to bind more 



































The key findings from the research presented in this dissertation are reproduced 
below: 
 
 Paper I. In this study we extrapolated the SCO-delivery properties of 
PepFect14 vector for the delivery of pDNA. This peptide efficiently 
formed nanoparticles with pDNA and induced efficient gene delivery in 
a variety of cell-lines, including primary cells. Moreover, we concluded 
that PF14/pDNA nanocomplexes were taken up by cells via class A 
scavenger receptors and caveolae-mediated endocytosis. 
 
 Paper II. In this study we modified several CPPs, including PF14, to 
provide tumor homing or include targeting peptides and assessed their 
ability to deliver genes within an in vitro BBB model. Coupling of the 
ANG peptide to truncated PF14 resulted in an efficient peptide, 
PepFect32, which exhibited both the highest transcytosis across the 
BBB in the in vitro model and the highest transfection efficacy in 
glioma cells. We concluded that this is the most efficient peptide-based 
vector for pDNA delivery across the BBB in this in vitro model. 
 
 Paper III. In this study we evaluated the effectiveness of the PF14 pep-
tide to deliver pDNA into several tissues after systemic administration. 
Furthermore, we aimed to improve its in vivo usability via PEGylation, 
where PEG was attached to PF14 via a peptide linker that is cleaved by 
enzymes overexpressed in tumors. This strategy enabled us to induce 
gene expression specifically in tumors, concomitantly leaving gene 
expression at baseline levels in other tissues. 
 
 Paper IV. In this study we explored additional strategies to improve 
PF14 mediated in vivo gene delivery and investigated various peptide 
parameters that could possibly influence the efficacy of gene induction 
in vivo. We characterized an optimal complex formulation that provided 
reduced side-effects while simultaneously leaving gene expression at 
high levels. By analyzing a range of PF14 analogs whose charge and 
fatty acid length were modified we found that both properties are 
simultaneously necessary for complex formation, stability against enzy-
matic attack, and gene delivery in both cell culture and after systemic 
administration in vivo. 
 
In conclusion, the research presented in this dissertation found that the CPP, 
PF14, can be utilized as a potent gene delivery vehicle in cell culture. This CPP 
is efficient not only in regular cell-lines, but also in primary cells, and in spe-
cific application such as in the in vitro BBB model. We also found that several 
parameters need to be optimized during the process of translating efficient in 
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vitro gene delivery to a platform for pre-clinical systemic gene delivery. These 
include the properties of the nanocomplexes, which should be biocompatible 
and have a minimum number of undesirable interactions. At the same time, 
these nanocomplexes should have an extended half-life while circulating in 
blood and sufficient stability against enzymatic attack. Last but not least, after 
optimizing these properties the complexes must still be able to transfect cells 
and overcome intracellular barriers such as endosomal escape and nuclear entry. 
During this research we developed an optimized PF14 based gene delivery plat-
form that can potentially be used to study gene therapy applications within rele-
vant genetic disease models.  
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SUMMARY IN ESTONIAN 
Rakku sisenevad peptiidid geeni transpordiks:  
transfektsioonist rakukultuuris geenitranspordiks  
in vivo tingimustes. 
Viimaste aastakümnete saavutused inimese genoomi täielikus sekveneerimises 
ja personaalmeditsiini väljatöötamisel on võimaldanud identifitseerida seoseid 
geneetiliste mutatsioonide ning nende poolt põhjustatud vigase geeniekspres-
siooni vahel. See on võimaldanud nukleiinhapetel (NH) põhinevate ravistratee-
giate arendamist, et reguleerida või parandada vigaseid geeniekspressiooni tase-
meid rakkudes. NHde toimetamine rakkudesse eeldab mitmete rakuväliste ning 
rakusiseste barjääride ületamist. Rakkudesse viidav funktsionaalne geen sisesta-
takse tavaliselt bakteriaalse päritoluga plasmiidi (pDNA), kuid füsikokeemiliste 
omaduste tõttu on pDNA rakku sisenemine piiratud ning tema bioloogilise 
aktiivsuse saavutamiseks on vajalik kasutada transportvektoreid. 
Geeni transportvektoreid on võimalik jagada vastavalt nende päritolule 
kaheks – viraalsed ning mitteviraalsed vektorid. Viraalsete vektorite põhiliseks 
eeliseks on efektiivsus, kuid patogeense päritolu tõttu on nende kasutamine alati 
seotud potentsiaalsete kõrval toimetega, lisaks, pole nad sobivad lühikeste 
sünteetiliste oligonukleotiidide (ON) transpordiks. See on viinud mitteviraalsete 
vektorite väljatöötamiseni, mis on tavaliselt lipiidsed või polümeersed katioon-
sed materjalid, mille põhiliseks omaduseks on kondenseerida pDNA nano-
suurusteks kompleksideks. On näidatud, et sellised vektorid on suhteliselt ohu-
tud, kuid mitte nii efektiivsed kui viraalsed vektorid. 
Üks võimalikke lahendusi sellele kesksele probleemile võib olla kuni 30 
aminohapet pikad peptiidsed ühendid, rakku sisenevad peptiidid (RSPd), mis 
suudavad rakkudesse viia väga erinevaid bioloogilisi ühendeid, seal hulgas 
NHsid. Positiivsed laengud ning hüdrofoobsed domeenid võimaldavad RSPdel 
kondenseerida NHsid nanosuurusteks osakesteks, mis seejärel sisenevad rakku-
desse peamiselt endotsütoosi teel. RSPd on väga efektiivsed geneetilise mater-
jali transportimisel rakukultuuris, kuid suurimaks väljakutseks on osutunud 
nende kasutatavus in vivo, kus lisaks rakusisestele takistusele tuleb RSP/NH 
kompleksidel vastu pidada vereringes leiduvatele lagundavatele ensüümidele, 
kõrval-efektide mõju organismile peab olema minimaalne ning lõpuks siht-
märkkoeni jõudes peavad olema säilinud omadused, mis võimaldavad rakke 
transfekteerida piisava efektiivsusega. Antud doktoritöö eesmärk on peptiididel 
põhineva transportsüsteemi kasutatavuse suurendamine in vivo, saavutamaks 
geeniekspressiooni, mis edasistes uuringutes võimaldaks rakendada RSP-de 
vahendatud geeniteraapiat haiguste ravimiseks loomses mudelis.  
Esimese töö eesmärk on uurida, kas RSPd, PepFect14 (PF14), on võimalik 
kasutada pDNA transpordiks. Selgus, et PF14 on võimeline pDNAd konden-
seerima negatiivse pinnalaenguga nanosuurusteks kompleksideks, mis on 
võimelised indutseerima kõrget geeniekspressiooni väga erinevates rakuliinides, 
seal hulgas raskesti transfekteeritavates primaarrakkudes. Sisenemisemehha-
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nismide väljaselgitamisel selgus, et kompleksid kasutavad rakkudesse sisene-
miseks klass A scavenger retseptoreid ning kaveoliin-vahendatud endotsütoosi. 
Teises töös uuriti RSP/pDNA komplekside potentsiaali läbida hematoentse-
faalset barjääri. Selleks sünteesiti rida RSPsid, seal hulgas PF14 põhinevaid 
analooge, mis sisaldasid hematoentsefaalses bärjääri spetsiifiliste retseptoritega 
seonduvaid peptiidseid järjestusi või glioblastoomi rakkudega seonduvaid pep-
tiide. Nende analoogide pDNA transpordi potentsiaali uurimiseks rakendati 
hematoentsefaalbaarjääri rakukultuuri mudelit. Kõige efektiivseima geenieks-
pressiooni indutseeris PF14 analoog, teiseks efektiivseimaks oli PF14 ilma 
modifikatsioonita. Need tulemused näitasid, et PF14l põhinev geenitransport on 
efektiivne ka spetsiifilistes rakendustes ning paindlik modifikatsioonidele, säili-
tades ka siis oma aktiivsuse.  
Kolmandas töös uuriti PF14ne potentsiaali transportida pDNAd in vivo. 
Süsteemse manustamise järgselt saavutati kõrge geeniekspresssioon kopsus, 
maksas ning ka põrnas. Akuutsete kõrvaltoimete esinemine viitas vajadusele 
optimeerida PF14-vahendatud geenitransporti. Lisaks oli eesmärgiks geeni 
transport spetsiifilistesse kudedesse, näiteks kasvajakoesse. Selle saavutamiseks 
PEGüleeriti (polüetüleenglükool ehk PEG molekuli lisamine) PF14 peptiid. See 
molekul võimaldab maskeerida peptiid/pDNA kompleks ebasoovitatavate inter-
aktsioonide eest vereringes, suurendades sellega sobivust ning poolväärtusaega, 
lisaks, võimaldab PEG molekul maskeerida PF14 universaalse transfektsiooni 
potentsiaali kopsudesse, maksa ning ülejäänud kudedesse. Selleks, et kompleks 
oleks võimeline transfekteerima ainult kasvajakude, lisati PEG molekul läbi 
peptiidse järjestuse, mis on substraadiks tuumori koes üle-ekspresseeritud 
spetsiifilistele ensüümidele. Kui maskeeritud peptiid/pDNA kompleks akumu-
leerub passiivselt kasvajakoesse siis ensüüm lõikab antud järjestust, mille tule-
musena PEG eemaldatakse, taastub PF14 transfektsiooni võime ning geen trans-
porditakse kasvajakoes olevatesse rakkudesse. Kasutades PEGüleerimisel põhi-
nevat aktiveeritavat süsteemi, saavutasime kasvajakoe spetsiifilise geeni-
ekspressiooni, ilma akuutsete toksiliste kõrvalmõjudeta ning antud transport-
süsteem on saadaval edasisteks eelkliinilisteks vähivastaste rakenduste 
uurimiseks.  
Neljandas töös uuriti lisavõimalusi parandamaks PF14/pDNA transporti 
pärast süsteemset manustamist ilma PEGülatsioonita, mis vähendab üldiselt 
transfektsiooni. Selleks optimeeriti RSP ja pDNA vahelist suhet nii, et võima-
likult suur osa peptiidist oleks pDNA vahendusel kompleksidesse seotud, kuna 
on varasemalt näidatud katioonsete polümeeride puhul, et kompleksidesse mitte 
seotud vaba fraktsioon polümeerist vahendab toksilisi kõrvalmõjusid. Samuti 
uurisime peptiidist tulenevaid omadusi, mis potentsiaalselt mõjutavad RSP/ 
pDNA komplekside transfektsiooni rakkudesse. Selleks sünteesiti erinevad ana-
loogid, milles oli muudetud katioonsete laengute hulk, teiseks, analoogid, mille 
rasvhappe jäägi pikkus oli muudetud. Nende mõjude uurimiseks kasutati erine-
vaid analüüsimeetodeid, mis võiks imiteerida in vivo tingimusi ning viimaks, 
hinnati nende peptiidide potentsiaali transportida pDNAd erinevatesse kude-
desse pärast süsteemset manustamist.  
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Selgus, et pDNA doosi suurendamine katioonse peptiidi fraktsiooni potent-
siaalseks vähendamiseks võimaldas indutseerida peaaegu sama kõrge geeni-
ekspressiooni organites ilma toksiliste kõrvalmõjudeta. Teiseks, ilmnes, et pep-
tiidi in vivo transfektiooni puhul on oluline samaaegselt nii piisav katioonne 
laeng kui ka rasvhappe jääk, mis võimaldavad efektiivselt moodustada 
komplekse RSP ja DNA vahel, suurendavad geenitranspordi efektiivsust raku-
kultuuris ning on piisavalt stabiilsed ensümaatilistele mõjutustele. Analoogid, 
mille katioonne laeng oli suurem või rasvhappe jääk pikem PF14st olid ainsana 
võimelised in vivo tingimustes geeniekspressiooni kudedes indutseerima.  
Kokkuvõtteks, RSPd on efektiivsed NH transportvektorid rakkudesse, kuid 
nende rakendamine loomsetes mudelites nõuab mitmel juhul lisamodifikat-
sioone ning optimeerimist. Siiski, on neil potentsiaal saavutada efektiivsus 
geeniteraapia läbiviimiseks geenimutatsioonidest tulenevate haiguste raviks 
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